NOVEL MALIGNANT CELL TYPE MARKERS OF THE INTERIOR NUCLEAR MATRIX

Abstract: Disclosed are genetic sequences and their encoded amino acid sequences for two interior nuclear matrix proteins useful as markers of malignant cell types. Primary and secondary structure analysis of the proteins is presented as well as means for their recombinant production, and compositions and methods for the use of these markers in clinical assays and cancer therapies.

Description: Novel Malignant Cell Type Markers of the Interior Nuclear Matrix Background of the Invention All eucaryotic cells, both plant and animal, have a nucleus surrounded by the cell cytoplasm. The nucleus contains the cellular DNA complexed with protein and termed chromatin. The chromatin, with its associated proteins, constitutes the major portion of the nuclear mass and is organized by the internal protein skeleton of the nucleus, referred to here as the nuclear matrix (NM). The nuclear matrix also is defined as the nuclear structure that remains following removal of the chromatin by digestion with DNase I and extraction with high salt. This skeletal nuclear structure further is characterized by the "interior nuclear matrix" (INM) and the bounding nuclear pore-lamina complex. Diverse studies have implicated the NM in a wide variety of nuclear functions fundamental to the control of gene expression (For a general review see, for example. Fey et al. (1991) Crit. Rev. Euk. Gene Express 1^:127-143). In particular, as described in U.S. Pat. Nos. 4,882,268 and 4,885,236, it is now known that certain nuclear matrix proteins, specifically interior nuclear matrix proteins, are useful as marker proteins for identifying cell types. For example, the presence and abundance of particular INM proteins have been shown to be characteristic of specific cell types and can be used to identify the tissue of origin of a cell or cell fragment present in a sample. One particularly important application of this discovery is the use of marker INM proteins in evaluating metastatic tissue. It is also known that the expression of certain INM proteins is altered in malignant or otherwise dysfunctional cells. The altered expression pattern of these proteins in maligrant and/or dysfunctioning cells also makes the proteins and nucleic acids encoding the proteins useful as marker proteins, alone or in combination, for diagnostic purposes and for evaluating tissue viability. US Pat. Nos. 4,882,268 and 4,885,236, issued 11/21/89 and 12/5/89, respectively, to Penman and Fey, disclose a method for selectively extracting insoluble INM proteins and their associated nucleic acids from cells or cellular debris and distinguishing the expression pattern of these proteins in a particular cell type by displaying the proteins on a two-dimensional electrophoresis gel. In addition, it recently has been discovered that INM proteins or protein fragments also may be released in soluble form from dying cells. (US Application Serial No. 785,804, filed October 31, 1991.) To date, molecular characterization of the specific proteins of the NM, particularly the INM, remain poorly defined due to the low abundance of these proteins in the cell and their generally insoluble character. The ability to isolate and characterize specific nuclear matrix proteins and the genetic sequences encoding them at the molecular level is anticipated to enhance the use of these proteins and their nucleic acids as marker molecules, and to enhance elucidation of the biological role of these proteins iji vivo. It is an object of this invention to provide genetic sequences encoding INM proteins useful as markers of malignant cell types. Another object is to provide enhanced means for identifying these proteins and their nucleic acids, including RNA transcripts, in samples. Yet another object of this invention is to provide compositions for use in diagnostic and other tissue evaluative procedures. Still another object is to provide genetic and amino acid sequences useful as target molecules in a cancer therapy. These and other objects and features of the invention will be apparent from the description, figures and claims which follow. Summary of the Invention Molecular characterization data, including DNA sequence data, for two INM proteins now have been derived from an expression library, using monoclonal antibodies for these proteins. The proteins, designated herein as MT1 and MT2, are present at elevated levels in malignant tissue and extracellular fluids. Accordingly, the proteins and the genetic sequences encoding them are thought to be useful as marker molecules for identifying tissue tumorgenesis in cell or body fluid samples. Full or partial clones of the genes encoding these proteins now have been isolated, and the DNA sequence, reading frames and encoded amino acid sequences of these DNAs determined. The DNA sequence for MT2 corresponds to the sequence disclosed by Yang, et al. (1992) J. Cell Biol. 116:1303-1317, and Compton et al. (1992) J. Cell Biol. 116:1395-1408, referred to therein as NuMA. The nucleic acid (and the encoded amino acid sequence) described herein for MT1 has not been described previously and also constitutes a novel sequence sharing little sequence homology with those sequences known in the art. In addition, MT1 has been subcloned into an expression vector, and the protein expressed as a cleavable fusion protein in E. coli. Both the MT1 and MT2 (NuMA) proteins are distributed throughout the nucleus (with the exception of the nucleolus) in non-mitotic cells, and localize to the spindle during mitosis, as determined immuno- fluoresence. The genetic sequences described herein provide a family of proteins for each of the proteins MTl and MT2, including allelic and species variants of MTl and MT2. The family of proteins include these proteins produced by expression in a host cell from recombinant DNA, the DNA itself, and the host cells harboring and capable of expressing these nucleic acids. The recombinantly produced proteins may be isolated using standard methodologies such as affinity chromatography to yield substantially pure proteins. As used herein, "substantially pure" is understood to mean substantially free of undesired, contaminating proteinaceous material. The family of proteins defined by MTl includes proteins encoded by the nucleic acid sequence of Seq. ID No. 1, including analogs thereof. As used herein, "analog" is understood to include allelic and species variants, and other naturally-occurring and engineered mutants. These variants include both biologically active and inactive forms of the protein. Particularly envisioned are DNAs having a different preferred codon usage, those having "silent mutations" of the DNA of Seq. ID No.l, wherein the changes in the genetic sequence do not affect the encoded amino acid sequence, and DNAs encoding "conservative" amino acid changes, as defined by Dayoff et al.. Atlas of Protein Sequence and Structure; vol. 5, Supp. 3, pp 345-362 (M.O. Dayoff, ed., Nat'l Biomed. Research Foundation, Washington, D.C. 1979.) Accordingly, the nucleic acids encoding the protein family of MTl may be defined as those sequences which hybridize to the DNA sequence of Seq. ID No.l under stringent hybridization conditions. As used herein. stringent hybridization conditions are as defined in Molecular Cloning: A Laboratory Manual, Maniatis, et al. eds.. Cold Spring Harbor Press, 1985, e.g.: hybridization in 50% formamide, 5x Denhardt's Solution, 5 x SSPE, 0.1% SDS and 100 μg/ml denatured salmon sperm, and washing in 2 x SSC, 0.1% SDS, at 37°C, and 1 x SSC, 0.1% SDS at 68°C. The family of proteins defined by MT2 includes proteins encoded by the nucleic acid sequence of Seq. ID No. 3, including analogs thereof, including allelic and species variants, and other naturally-occurring and engineered mutants. These variants include both biologically active and inactive forms of the protein. Particularly envisioned are DNAs having silent mutations, other preferred codon usages, and DNAs encoding conservative amino acid changes. The nucleic acids encoding the protein family of MT2 of this invention may be defined as those sequences which hybridize with the DNA sequence of Seq. ID No. 3 under stringent hybridization conditions. In another aspect, the invention provides nucleic acid fragments ("oligonucleotides" or "oligomers") which hybridize to genetic sequences encoding MTl, but which do not necessarily encode functional proteins themselves. The oliognucleotides include probes for isolating genetic sequences encoding members of the MTl family of proteins from a cDNA or genomic DNA library, and/or for identifying genetic sequences naturally associated with the MTl protein coding sequence e.g., sequences lying upstream or downstream from the coding sequences. For example, where the nucleic acid fragment is to be used as a probe to identify other members of the MTl family, the nucleic acid fragment may be a degenerate sequence as described in Molecular Cloning: A Laboratory Manual, Maniatis, et al. eds.. Cold Spring Harbor Press, 1985, designed using the sequence of Seq. ID No.l as a template. Accordingly, the oligonucleotide or nucleic acid fragment may comprise part or all of the DNA sequence of Seq. ID No. 1, or may be a biosynthetic sequence based on the DNA sequence of Seq. ID No. 1. The oligonucleotide preferably is suitably labelled using conventional labelling techniques. The oligonucleotides also include sequences which hybridize with the mRNA transcript encoding the MTl protein. These complementary sequences are referred to in the art and herein as antisense sequences. Antisense sequences may comprise part or all of the sequence of Seq. ID No. 1, or they may be biosynthetic sequences designed using the sequence of Seq. ID No. 1 as a template. In still another aspect, the invention provides oligonucleotides which hybridize to the genetic sequences encoding members of the MT2 protein family. The fragments include antisense sequences and sequences useful as probes for identifying members of the MT2 f mily and/or for identifying associated^noncoding sequences. The hybridizing nucleic acids may comprise part or all of the sequence of Seq. ID No. 3 or may be biosynthetic sequences designed using the DNA sequence of Seq. ID No. 3 as a template, preferably suitably labelled using conventional techniques. The genetic sequences identified herein encode proteins identified as marker proteins indicative of a malignancy or other cellular dysfunction in a tissue. Thus, in another aspect, the invention provides compositions for obtaining antibodies useful for detecting cancer marker proteins in a sample using the proteins described herein in combination with a suitable adjuvant. In another aspect, the invention provides genetic templates for designing sequences which hybridize specifically with the mRNA transcripts encoding these proteins. In still another aspect, the invention provides isolated DNA sequences for use in expressing proteins and protein fragments for the design of binding proteins, including antibodies, which interact specifically with an epitope on MTl or MT2. The invention also provides methods for evaluating the status of a tissue using the genetic sequences described herein, and the marker proteins encoded by them. Finally, the invention provides methods for treating a malignancy in an individual using these marker proteins, or the genetic sequences encoding them, as target molecules to inhibit or disable the cell's ability to undergo cell division. Brief Descriptions of the Drawings Fig. 1A-1D is a schematic representation of the amino acid sequence of MTl of Seq. ID No.l, showing: Fig. IA: the location of the proline residues; Fig. IB: the areas defined as "--helices within the sequence; Fig. IC: the location of the cysteine residues; and Fig. ID: the sites of cleavage by NTCB; Fig. 2A-2B is a schematic representation of the amino acid sequence of MT2 of Seq. ID No.3, showing: Fig. 2A: the location of proline residues; and Fig. 2B: the areas defined as «-helices within the sequence; Fig. 3: lists the levels of body fluid-soluble MT2 and MT2-associated'protein quantitated in various normal and malignant tissue sample supernatants; and Fig. 4: lists the levels of body fluid-soluble MT2 and MT2-associated protein quantitated in sera isolated from cancer patients and normal blood donors. Detailed Description In an attempt to characterize INM proteins useful as malignant cell markers in biological assays, the genetic sequences encoding two INM proteins, herein referred to as MTl and MT2, now have been identified and characterized. DNA sequences encoding these proteins now have been cloned by probing expression libraries using monoclonal antibodies raised against the isolated INM proteins MTl and MT2. The proteins were isolated from malignant cells essentially following the method of Penman and Fey, described in U.S. Pat. Nos. 4,882,268 and 4,885,236, the disclosures of which are herein incorporated by reference. The cloned DNAs, then were sequenced and their reading frames identified and analyzed. The genetic sequence encoding MT2 also has been disclosed by others (Yang, et al. (1992) J. Cell Biol. 116:1303-1317 and Compton et al. (1992) J. Cell. Biol. 116:1395-1408), and is referred to by them as "NuMA". Comparison of MTl and MT2 (NuMA) with other sequences in the art indicate that the sequences encoding these proteins constitute sequences sharing little homology with previously described sequences. MTl also has been expressed as a cleavable fusion protein in E_ ; _ coli and compared with the protein isolated from mammalian cells. Anti-MTl antibodies raised against the natural-sourced MTl protein also crossreact with the recombinantly produced protein. Both the natural-sourced and recombinantly produced proteins have the same apparent molecular weight when analyzed by SDS-PAGE (90kD), equivalent pi values (5.4), and both proteins show the same cleavage pattern when cleaved with 2-nitro-3-thiocyanobenzoic acid (NTCB, see infra.) Immunolocalization data on MTl indicates that MTl protein is distributed within the INM in non-mitotic cells as discrete punctate foci, nonuniformly distributed throughout the nucleoplasm of the INM. Specifically, the foci are present in the interchromatinic regions of the nucleus and are distributed in a stable association that remains after chromatin extraction, as is anticipated for an interior nuclear matrix protein. In addition, MTl foci are excluded from the nucleolus and the nuclear lamina. Moreover, during mitosis, the distribution of MTl changes and MTl becomes aligned in a stellate or star- shaped pattern at the spindle of the dividing cell. The protein does not co-localize with the chromosomes, suggesting that MTl may play a structural role during mitosis. The immunolocalization data is consistent with the MTl amino acid sequence analysis data which fails to find structural homology with any known DNA binding motifs, such as the "leucine zipper." While the MT2 (NuMA) protein has not yet been recombinantly expressed, the predicted molecular weight of 238 kDa for this protein, calculated from the predicted amino acid sequence (see Seq. ID No. 3), agrees with that of the natural-sourced material. Immunolocalization studies on MT2 (NuMA) indicate that it also forms punctate foci located throughout the nucleoplasm of the non-mitotic cell, and also is excluded from the nucleolus. During mitosis the protein appears to migrate to the spindle poles of the dividing cell. The primary sequence appears to suggest a coiled-coil motif for the folded protein (Compton, et al. (1992) J. Cell Biol. 116:1395-1408; Yang, et al. (1992) J. Cell Biol. 116:1303-1317.) I. How to Use The nucleic acids disclosed herein encode proteins originally identified as marker proteins useful for identifying cell malignancies or other cell abnormalties. Specifically, significantly elevated levels of these proteins are detected in malignant cells and in extracellular fluids, e.g., sera, of cancer patients. (See PCT publication WO93/09437 and infra.) For example, the presence and/or abundance of these proteins or their transcripts in a sample containing cells or cell nuclear debris may be used to determine whether a given tissue comprises malignant cells or cells having other abnormalities, such as chromosomal abnormalities. The sample may be an exfoliated cell sample or a body fluid sample, e.g., a sample comprising blood, serum, plasma, urine, semen, vaginal secretions, spinal fluid, saliva, ascitic fluid, peritoneal fluid, sputum, tissue swabs, and body exudates such as breast exudate. In addition, because INM proteins are released in soluble form from dying cells, the marker molecules may be used to evaluate the viability of a given tissue. For example, the marker proteins may be used to evaluate the status of a disease or the efficacy of a therapeutic treatment or procedure, by monitoring the release of these marker molecules into a body fluid over a period of time. Particularly useful body fluids include blood, serum, plasma, urine, semen, vaginal secretions, spinal fluid, saliva, ascitic fluid, peritoneal fluid, sputum, tissue swabs, and body exudates such as breast exudate. Methods for performing these assays are disclosed in U.S. Pat. Nos. 4,882,268 and 4,885,236 and in co-pending U.S. application Serial Nos. 214,022, filed June 30, 1988 and U.S. application Serial No. 785,804, filed October 31, 1991, the disclosures of which all are herein incorporated by reference. All of these assays are characterized by the following general procedural steps: 1) detecting the presence and/or abundance of the marker protein or its transcript in "authentic" or reference samples; 2) detecting the presence and/or abundance of the marker protein or its transcript in the sample of interest; and 3) comparing the quantity of marker protein or its transcript in the sample of interest with the quantity present in the reference sample. Where the assay is used to monitor tissue viability, the step of detecting the presence and abundance of the marker protein or its transcript in samples of interest is repeated at intervals and these values then are compared, the changes in the detected concentrations reflecting changes in the status of the tissue. Where the assay is used to evaluate the efficacy of a therapy, the monitoring steps occur following administration of the therapeutic agent or procedure (e.g., following administration of a chemotherapeutic agent or following radiation treatment. ) It is not required that the selected marker protein or transcript be totally unique, in the sense that the particular INM marker molecule is present in the target cell type and in no other. Rather, it is required that the marker molecule have a signal to noise ratio high enough to discriminate the preselected cell type in samples for which the assay is designed. For example, MTl and MT2 proteins are useful as proteins indicating the presence of malignancy in cell samples because of their elevated expression levels in malignant cells, even though the proteins, or close analogs thereof, may be present commonly in nonmalignant cell types. A brief description of general protein and nucleic acid assay considerations follows below. Details of particular assay conditions may be found in the assay references described above and incorporated herein by reference, and in published protocols well known in the art and readily available. A. Protein Assays Characterization of the MTl and MT2 proteins at the molecular level as described herein allows one to characterize the proteins structurally and biochemically. Accordingly, following the disclosure of these genetic sequences and their encoded amino acid sequences, preferred binding epitopes may be identified which may be used to enhance assay conditions. For example, binding proteins may be designed which have enhanced affinity for the marker protein produced by particular cell types or as a function of particular malignancies. Similarly, binding proteins may be designed which bind preferentially to protein fragments released from dying cells. In addition, structural and/or sequence variations between proteins produced in normal and abnormal tissue now may be investigated and used to advantage. The genetic sequences may be manipulated as desired, e.g., truncated, mutagenized or the like, using standard recombinant DNA procedures known in the art, to obtained proteins having desired features useful for antibody production. As will be appreciated by those skilled in the art, any means for specifically identifying and quantifying a marker protein of interest is contemplated. The currently preferred means for detecting a protein of interest in a sample is by means of a binding protein capable of interactingSpecifically with the marker protein. Labelled antibodies or the binding portions thereof in particular may be used to advantage. The antibodies may be monoclonal or polyclonal in origin, or may be biosynthetically produced. The amount of complexed marker protein, e.g., the amount of marker protein associated with the binding protein, then is determined using standard protein detection methodologies well described in the art. A.l. Immunoassays A variety of different forms of immunoassays currently exist, all of which may be adapted to detect and quantitate INM proteins and protein fragments. For exfoliated cell samples, as an example, the cells and surrounding fluid are collected and the INM proteins selectively isolated by the method of Penman and Fey, described in U.S. Pat. Nos. 4,882,268 and 4,885,236. These proteins then preferably are separated by two- dimensional gel electrophoresis and the presence of the marker protein detected by standard Western blot procedures. For serum and other fluid assays where the marker proteins and/or protein fragments to be detected exist primarily in solution, one of the currently most sensitive immunoassay formats is the sandwich technique. In this method, as described in PCT publication WO93/09437 and which has a precision typically of + 5%, two antibodies capable of binding the analyte of interest generally are used: e.g., one immobilized onto a solid support, and one free in solution, but labeled with some easily detectable chemical compound. Examples of chemical labels that may be used for the second antibody include radioisotopes, fluorescent compounds, and enzymes or other molecules which generate colored or electrochemically active products when exposed to a reactant or enzyme substrate. When samples containing the marker protein or protein fragment are placed in this system, the marker protein binds to both the immobilized antibody and the labelled antibody. The result is a "sandwich" immune complex on the support's surface. The complexed protein is detected by washing away nonbound sample components and excess labeled antibody, and measuring the amount of labeled antibody complexed to protein on the support's surface. The sandwich immunoassay is highly specific and very sensitive, provided that labels with good limits of detection are used. A detailed review of immunological assay design, theory and protocols can be found in numerous texts in the art, including Practical Immunology, Butt, W.R., ed.. Marcel Dekker, New York, 1984. In general, immunoassay design considerations include preparation of antibodies (e.g., monoclonal or polyclonal) having sufficiently high binding specificity for their antigen that the specifically- bound antibody-antigen complex can be distinguished reliably from nonspecific interactions. As used herein, "antibody" is understood to include other binding proteins having appropriate binding affinity and specificity for the marker protein. The higher the antibody binding specificity, the lower the antigen concentration that can be detected. Currently preferred binding specificity is such that the binding protein has a binding affinity for the marker protein of greater than about 10 5 M " 1 , preferably greater than about 10 7 M _1 . Antibody binding domains also may be produced biosynthetically and the amino acid sequence of the binding domain manipulated to enhance binding affinity with a preferred epitope. Identification of the genetic sequences for MTl and MT2 can be used to advantage in the design and construction of preferred binding proteins. For example, a DNA encoding a preferred epitope may be recombinantly expressed and used to select an antibody which binds selectively to the eptiope. The selected antibodies then are exposed to the sample under conditions sufficient to allow specific binding of the antibody to its specific nuclear matrix protein or protein fragment, and the amount of complex formed then detected. Specific antibody methodologies are well understood and described in the literature. A more detailed description of their preparation can be found, for example, in Practical Immunology, Butt, W.R., ed., Marcel Dekker, New York, 1984. The choice of tagging label also will depend on the detection limitations desired. Enzyme assays (ELISAs) typically allow detection of a colored product formed by interaction of the enzyme-tagged complex with an enzyme substrate. Alternative labels include radioactive or fluorescent labels. The most sensitive label known to date is a chemiluminescent tag where interaction with a reactant results in the production of light. Useful labels include chemiluminescent molecules such as acridium esters or chemiluminescent enzymes where the reactant is an enzyme substrate. When, for example, acridium esters are reacted with an alkaline peroxide solution, an intense flash of light is emitted, allowing the limit of detection to be increased 100 to 10,000 times over those provided by other labels. In addition, the reaction is rapid. A detailed review of chemiluminescence and immunoassays can be found in Weeks, et al., (1983) Methods in Enzymology 133:366-387. Other considerations for fluid assays include the use of microtiter wells or column immunoassays. Column assays may be particularly advantageous where rapidly reacting labels, such as chemiluminescent labels, are used. The tagged complex can be eluted to a post-column detector which also contains the reactant or enzyme substrate, allowing the subsequent product formed to be detected immediately. A.2. Antibody Production The proteins described herein may be used to raise antibodies using standard immunological procedures well known and described in the art. See, for example. Practical Immunology, Butt, N.R., ed., Marchel Dekker, NY, 1984. Briefly, an isolated INM protein produced, for example, by recombinant DNA expression in a host cell, is used to raise antibodies in a xenogenic host. Preferred antibodies are antibodies that bind specifically to an epitope on the protein, preferably having a binding affinity greater than 10 5 M _1 , most preferably having an affinity greater than 10 7 M _1 for that epitope. For example, where antibodies to a human INM protein, e.g. MTl or MT2 is desired, a suitable antibody generating host is a mouse, goat, rabbit, guinea pig, or other mammal useful for generating antibodies. The protein is combined with a suitable adjuvant capable of enhancing antibody production in the host, and injected into the host, for example, by intraperitoneal administration. Any adjuvant suitable for stimulating the host's immune response may be used to advantage. A currently preferred adjuvant is Freund's complete adjuvant (an emulsion comprising killed and dried microbial cells, e.g., from Calbiochem Corp., San Diego, or Gibco, Grand Island, NY). Where multiple antigen injections are desired, the subsequent injections comprise the antigen in combination with an incomplete adjuvant (e.g. cell-free emulsion). Polyclonal antibodies may be isolated from the antibody-producing host by extracting serum containing antibodies to the protein of interest. Monoclonal antibodies may be produced by isolating host cells that produce the desired antibody, fusing these cells with myeloma cells using standard procedures known in the immunology art, and screening for hybrid cells (hybridomas) that react specifically with the INM protein and have the desired binding affinity. Provided below is an exemplary protocol for monoclonal antibody production, which is currently preferred. Other protocols also are envisioned. Accordingly, the particular method of producing antibodies with the cancer marker protein compositions of this invention, is not envisioned to be an aspect of the invention. Also described below are exemplary sandwich immunoassays and dot blot assays useful for detecting and/or quantitating marker proteins in a sample. Other means for detecting marker proteins, particularly MTl, MT2 and their analogs, including protein fragments and naturally-occurring variants, also are envisioned. These other methods are well-known and described in the art. Exemplary antibody production protocol: Balb/c by J mice (Jackson Laboratory, Bar Harbor, ME) are injected intraperitoneally with purified INM protein (e.g., MTl) purified from the human cervical cell line CaSki, every 2 weeks for a total of 16 weeks. The mice are injected with a single boost 4 days prior to sacrifice and removal of the spleen. Freund's complete adjuvant (Gibco, Grand Island) is used in the first injection, incomplete Freund's in the second injection; subsequent injections are made with saline. Spleen cells (or lymph node cells) then are fused with a mouse myeloma line, e.g., using the method of Kohler and Milstein (1975) Nature 256:495, the disclosure of which is incorporated herein by reference, and using polyethylene glycol (PEG, Boehringer Mannheim, Germany). Hybridomas producing antibodies that react with nuclear matrix proteins then are cloned and grown as ascites. Hybridomas are screened by nuclear reactivity against the cell line that is the source of the immunogen, and by tissue immunochemistry using standard procedures known in the immunology art. Detailed descriptions df screening protocols, ascites production and immunoassays also are disclosed in PCT publication WO93/09437. Exemplary Assays: A. Sandwich Immunoassay (ELISA) A standard immunoassay can be performed to generate dose response curves for antigen binding, for cross reactivity assays, and for monitoring assays. The data is generated with a standard preparation of NM antigen, and is used as the reference standard when body fluids are assayed. In these examples both ELISAs and radioummunoassays were performed. 1. Immunoassay (Well Assay) Microtitre plates (Immulon II, Dynatech, Chantilly, VA) are coated with purified antibody at 5 to 15ug/ml in PBS at pH 7.4 for lhr or overnight and then washed 3 x with 300μl PBS. The plates then are blocked with 10% normal goat serum in PBS for lhr at room temp and washed 3 x with 300μl of PBS. An exemplary protocol follows. Here, samples are assayed by pipetting lOOμl of sample per well, and incubating for lhr at RT. The wells were washed with 3 x 300μl PBS. lOOμl of 1.25 to lOμg/ml of a biotinylated antibody added to each well, incubated for lhr at RT and washed with 3 x 300μl of PBS. lOOμl of a 1:1000 dilution of streptavidin- horseradish peroxidase conjugate (The Binding Site Ltd., Birmingham, UK) added to each well and incubated for lhr and then washed with PBS. lOOμl of peroxidase substrate (citrate, phosphate, OPD-H 2 0 2 ) then is added to each well and incubated for 20min. The reaction is stopped by adding 50μl of 1M H 2 S0. to the wells. The optical density is read on a plate reader at 490nm. Concentrations of antigen are determined by preparing a reference concentration of antigen and preparing a standard dilution curve to compare with the unknown samples. 2. IRMA (Immunoradiometric Assay) (a) Iodination of Streptavidin. lOμg of streptavidin (Sigma, Inc., Cincinnati) in 2μl of 0.05M phosphate pH 7.4 was added to lOμl of 0.25M phosphate pH 7.4 in a microcentrifuge tube and lmCi of 125 I (NEN-DUPONT, Wilmington, DE) in lOμl is added. Immediately lOμl of lOOmg chloramine-T trihydrate (Sigma, Inc.) in 50ml of distilled water is added, mixed, and reacted for 25sec. The reaction then is stopped by mixing for 20sec with 50μl of 40mg Cysteamine (2-mercaptoethlyamine) (Sigma, Inc.) and 5mg KI in 50ml of 0.05M phosphate pH 7.4. 0.5ml of 1% BSA in PBS pH 7.4 added and the material fractionated on a 10ml sephadex G-100 column (Pharmacia, Sweden) pre- equilibrated with the BSA PBS buffer. 30 by 0.5ml fractions are collected and lOμl diluted to 1ml of the BSA/PBS buffer for each fraction. lOOμl of the diluted fraction is counted on a LKB gamma counter set for 125 I. The specific activity is calculated and routinely falls between 85 to lOOuCi/ug. The mid fractions of the protein peak then are used in the sandwich immunoassay. (b) Sandwich Radioimmunoassay. The microtitre breakaway wells (Immulon II Removawell strips, Dynatech, Chantilly, Va) are coated and blocked as in the ELISA assay. The samples, standard or sera, are routinely measured by incubating lOOμl in the wells for lhr at RT washing on a plate washer with 3 x 300μl of PBS and then incubated with the biotinylated antibody (2-10μg/ml in 10% goat serum) for lhr at RT and washed again. The bound biotinylated antibody is detected with the 125 I-streptavidin. 200,000 to 300,000 cpm (77% counter efficiency) in lOOμl is added to each well and incubated for lhr at RT and washed again. The bound fraction is detected by counting the radioactivity in an LKB gamma counter. The concentration can be determined by comparing the counts obtained against a reference preparation. B. Dot Blot Detection of NM. Antibody reactivity with NM proteins can be assessed by dot blot detection assays, using standard methodologies and apparatus (e.g. ,Schleicher & Schuell). Nitrocellulose membranes are soaked in Tris buffered saline, (TBS, 50mM TRIS, 150mM NaCl, pH 7.6) and NM preparation applied at varying concentrations of protein to a series of wells and incubated for lhr at room temperature (e.g., T-47D NM supernatant at lOμg/ml, lμg/ml and lOOng/ml). The blocked wells then are washed with 2 x 200μl of TBS and then blocked with lOOμl 10% normal goat serum in TBS for lhr at room temperature. The blocked wells then are washed again with 2 x 200μl of TBS and lOOμl of culture supernatant containing nuclear reactive antibody to be tested is added to their respective wells and incubated for lhr at room temperature. The wells then are washed with 2 x 200μl of TBS and lOOμl of a dilution series of alkaline phosphatase conjugated goat anti-mouse IgG (Bio-Rad, Richmond, CA) (e.g., 1:1000, 1: 5000, or 1:10000) added to the relevant wells and incubated for lhr. The wells then are washed with 2 x 200μl of TBS followed by addition of enzyme substrate (BCIP/NBT, Kirkgaard and Perry, Gaithersburg, MD, e.g., 100 μl) in Tris buffer containing Levamisole (Vector, Inc., Corpus Christi, TX. ) A fifteen minute incubation generally is sufficient. The reaction can be stopped by washing with distilled water and the product detected. B. Nucleic Acid Assays The status of a tissue also may be determined by detecting the quantity of transcripts encoding these cancer marker proteins. The currently preferred means for detecting mRNA is by means of northern blot analysis using labeled oligonucleotides e.g., nucleic acid fragments capable of hybridizing specifically with the transcript of interest. The currently preferred oligonucleotide sequence is a sequence encoding a complementary sequence to that of at least part of the transcript marker sequence. These complementary sequences are known in the art as "antisense" sequences. The oligonucleotides may be oligoribonucleotides or oligodeoxyribonucleotides. In addition, oligonucleotides may be natural oligomers composed of the biologically significant nucleotides, i.e., A (adenine), dA (deoxyadenine), G (guanine), dG (deoxyguanine) , C (cytosine), dC (deoxycytosine) , T (thymine) and U (uracil), or modified oligonucleotide species, substituting, for example, a methyl group or a sulfur atom for a phosphate oxygen in the inter- nucleotide phosohodiester linkage, (see, for example. Section I.C, below.) Additionally, the nucleotides themselves, and/or the ribose moieties may be modified. The sequences may be synthesized chemically, using any of the known chemical oligonucleotide synthesis methods well described in the art. For example, the oligonucleotides are advantageously prepared by using any of the commercially available, automated nucleic acid synthesizers. Alternatively, the oligonucleotides may be created by standard recombinant DNA techniques, by, for example, inducing transcription of the noncoding strand. For example, the DNA sequence encoding a marker protein may be inverted in a recombinant DNA system, e.g., inserted in reverse orientation downstream of a suitable promoter, such that the noncoding strand now is transcribed. Useful hybridizing oligonucleotide sequences include any sequences capable of hybridizing specifically to the MTl or MT2 primary transcripts. Accordingly, as will be appreciated by those skilled in the art, useful sequences contemplated include both sequences complementary to the DNA sequences provided in Seq. ID No. 1 (MTl) or Seq. ID No. 3 (MT2) which correspond to the protein coding regions, as well as sequences complementary to transcript sequences occurring further upstream or downstream from the coding sequence (e.g., sequences contained in, or extending into, the 5'- and 3' untranslated regions). Representative antisense sequences are described in Seq. ID Nos. 5 and 6. Seq. ID No. 5 describes a sequence complementary to the first 100 nucleotides of the MTl protein coding sequence (compare Seq. ID Nos. 1 and 5) as well as the 53 nucleotide sequence occurring upstream of the initiation codon. The complementary nucleotides to the initiation codon occur at positions 298-300 in Seq. ID No. 5. Similarly, Seq. ID No. 6 describes a sequence complementary to the first 100 nucleotides of the MT2 protein coding sequence (compare Seq. ID Nos. 3 and 6), as well as the 48 nucleotide sequence occurring upstream of the initiation codon. The complementary nucleotides to the initiation codon occur at positions 298-300 in Seq. ID No. 6. Useful oligomers may be created based on part or all of the sequences in Seq. ID No. 5 and 6. However, as will be appreciated by those skilled in the art, other useful sequences which hybridize to other regions of the transcript readily are created based on the sequences presented in Seq. ID Nos. 1 and 3 and/or additional, untranslated sequences, such as are disclosed for MT2 (NuMA) in Compton et al. and Yang et al. While any length oligonucleotide may be utilized to hybridize an mRNA transcript, sequences less than 8-15 nucleotides may be less specific in hybridizing to target mRNA. Accordingly, oligonucleotides typically within the range of 8-100 nucleotides, preferably within the range of 15-50, nucleotides are envisioned to be most useful in standard RNA hybridization assays. The oligonucleotide selected for hybridizing to the INM transcript, whether synthesized chemically or by recombinant DNA, then is isolated and purified using standard techniques and then preferably labelled (e.g., with 35 S or 32 P) using standard labelling protocols. A sample containing the marker transcript of interest then is run oh an electrophoresis gel, the dispersed nucleic acids transferred to a nitrocellulose filter and the labelled oligonucleotide exposed to the filter under suitable hybridizing conditions, e.g. 50% formamide, 5 X SSPE, 2 X Denhardt's solution, 0.1% SDS at 42°C, as described in Molecular Cloning: A Laboratory Manual, Maniatis et al. Other useful procedures known in the art include solution hybridization, and dot and slot RNA hybridization. The amount of marker transcript present in a sample then is quantitated by measuring the radioactivity of hybridized fragments, using standard procedures known in the art. Following a similar protocol, oligonucleotides also may be used to identify other sequences encoding members of the MTl and MT2 protein families, for example, as described in the examples that follow. The methodology also may be used to identify genetic sequences associated with the protein coding sequences described herein, e.g., to identify noncoding sequences lying upstream or downstream of the protein coding sequence, and which may play a functional role in expression of these genes. Where new marker species are to be identified, degenerate sequences and/or sequences with preferred codon bias may be created, using the sequences of Seq. ID Nos. 1 or 3 as templates, and the general guidelines described in the art for incorporating degeneracies. (See, for example. Molecular Cloning: A Laboratory Manual, Maniatis, et al. ) C. Therapeutics The proteins described herein are associated with the spindle apparatus during mitosis, and are present at elevated levels in malignant cells. Accordingly, without being limited to any particular theory, it is hypothesized that the proteins likely play a significant role in cell division, most likely a structurally related role. Accordingly, these proteins and their transcripts are good candidates as target molecules for a cancer chemotherapy. Cl Antisense Therapeutics A particularly useful cancer therapeutic envisioned is an oligonucleotide complementary to part all of the marker transcript, capable of hybridizing specifically to the transcript and inhibiting translation of the mRNA when hybridized to the mRNA transcript. Antisense oligonucleotides have been used extensively to inhibit gene expression in normal and abnormal cells. See, for example. Stein et al. (1988) Cancer Res. 48:2659-2668, for a pertinent review of antisense theory and established protocols. Accordingly, the antisense nucleotides to MTl and MT2 may be used as part of chemotherapy, alone or in combination with other therapies. As described in Section I.B above, both oligoribonucleotide and oligodeoxyribonucleotide sequences will hybridize to an MRNA transcript and may be used to inhibit mRNA translation of the marker protein described herein. However, oligoribonucleotides generally are more susceptible to enzymatic attack by ribonucleases than deoxyribonucleotides. Hence, oligodeoxyribonucleotides are preferred for in vivo therapeutic use to inhibit mRNA translation in an individual. Also, as described in Section I.B above, the therapeutically useful antisense oligonucleotides of the invention may be synthesized by any of the known chemical oligonucleotide synthesis methods well described in the art. Alternatively, a complementary sequence to part or all of the natural mRNA sequence may be generated using standard recombinant DNA technology. For example, the DNA encoding the protein coding sequence may be inserted in reverse orientation downstream of a promoter capable of expressing the sequence such that the noncoding strand is transcribed. Since the complete nucleotide sequence of the protein coding sequence as well as additional 5' and 3' untranslated sequences are known for both MTl and MT2 (see, for example, Seq. ID Nos. 1 and 3 and Compton et al.), and/or can be determined with this disclosure, antisense oligonucleotides hybridizable with any portion of the mRNA transcripts to these proteins may be prepared using conventional oligonucleotide synthesis methods known to those skilled in the art. Oligonucleotides complementary to and hybridizable with any portion of the MTl and MT2 mRNA transcripts are, in principle, effective for inhibiting translation of the transcript as described herein. For example, as described in U.S. Pat. No. 5,098,890, issued March 24, 1992, the disclosure of which is incorporated herein by reference, oligonucleotides complementary to mRNA at or near the translation initiation codon site may be used to advantage to inhibit translation. Moreover, it has been suggested that sequences that are too distant in the 3' direction from the translation initiation site may be less effective in hybridizing the mRNA transcripts because of potential ribosomal "read- through", a phenomenon whereby the ribosome is postulated to unravel the antisense/sense duplex to permit translation of the message. Representative antisense sequences for MTl and MT2 transcripts are described in Seq. ID No. 5 (MTl) and Seq. ID No. 6 (MT2). The antisense sequences are complementary the sequence encoding the N-terminus of either the MTl or MT2 marker protein, as well as part of the 5' untranslated sequences immediately upstream of the initiation codon. (See Section I.B, above for a detailed description of these sequences). As will be appreciated by those skilled in the art, antisense oligonucleotides complementary to other regions of the MTl and/or MT2 transcripts are readily created using for example, the sequences presented in Seq. ID No. 1 and 3 as templates. As described in Section I.B above, any length oligonucleotide may be utilized to hybridize to mRNA transcripts. However, very short sequences (e.g., less than 8-15 nucleotides) may bind with less specificity. Moreover, for ij vivo use such short sequences may be particularly susceptible to enzymatic degradation. In addition, where oligonucleotides are to be provided directly to the cells, very long sequences may be less effective at inhibition because of decreased uptake by the target cell. Accordingly, where the oligonucleotide is to be provided directly to target cells, oligonucleotides having a length within the range of 8-50 nucleotides, preferably 15-30 nucleotides, are envisioned to be most advantageous. An alternative means for providing antisense sequences to a target cell is as part of a gene therapy technique, e.g., as a DNA sequence, preferably part of a vector, and associated with a promoter capable of expressing the antisense sequence, preferably constitutively, inside the target cell. Recently, Oeller et al. ((1992) Science 254:437-539, the disclosure of which is in corporated by reference) described the ii vivo inhibition of the ACC synthase enzyme using a constitutively expressible DNA sequence encoding an antisense sequence to the full length ACC synthase transcript. Accordingly, where the antisense sequences are provided to a target cell indirectly, e.g., as part of an expressable gene sequence to be expressed within the cell, longer oligonucleotide sequences, including sequences complementary to substantially all the protein coding sequence, may be used to advantage. Finally, also as described in Section I.B, above, the therapeutically usefully oligonucleotides envisioned include not only native oligomers composed of naturally occurring nucleotides, but also those comprising modified nucleotides to, for example, improve stability and lipid solubility and thereby enhance cellular uptake. For example, it is known that enhanced lipid solubility and/or resistance to nuclease digestion results by substituting a methyl group or sulfur atom for a phosphate oxygen in the internucleotide phosphodiester ^ linkage. Phosphorothioates ("S-oligonucleotides" wherein a phosphate oxygen is replaced by a sulfur atom), in particular, are stable to nuclease cleavage, are soluble in lipids, and are preferred, particularly for direct oligonucleotide administration. S-oligonucleotides may be synthesized chemically by the known automated synthesis methods described in Section I.B, above. Suitable oligonucleotide sequences for mRNA translation inhibition are readily evaluated by a standard in vitro assay using standard procedures described herein and well characterized in the art. An exemplary protocol is described below, but others are envisioned and may be used to advantage. A candidate antisense sequence is prepared as provided herein, using standard chemical techniques. For example, an MTl antisense sequence may be prepared having the sequence described by positions 285-315 of Sequence ID No. 5 using an Applied Biosystems automated DNA Synthesizer, and the oligonucleotide purified accordingly to manufacturer's instructions. The oligonucleotide then is provided to a suitable malignant cell line in culture, e.g., ME-180, under standard culture conditions, to be taken up by the proliferating cells. Preferably, a range of doses is used to determine effective concentrations for inhibition as well as specificity of hybridisation. For example, a dose range of 0-100 μg oligonucleotide/ml may be assayed. Further, the oligonucleotides may be provided to the cells in a single transfection, or as part of a series of transfections. Antisense efficacy may be determined by assaying a change in cell proliferation over time following transfection, using standard cell counting methodology and/or by assaying for reduced expression of marker protein, e.g., by immunofluorescence, as described in Section I.A, above. Alternatively, the ability of cells to take up and use thymidine is another standard means of assaying for cell division and maybe used here, e.g., using 3 H thymidine. Effective antisense inhibition should inhibit cell division sufficiently to reduce thymidine uptake, inhibit cell proliferation, and/or reduce detectable levels of marker proteins. Useful concentration ranged are envisioned to vary according to the nature and extent of the neoplasm, the particular oligonucleotide utilized, the relative sensitivity of the neoplasm to the oligonucleotides, and other factors. Useful ranges for a given cell type and oligonucleotide may be determined by performing a standard dose range experiment as described here. Dose range experiments also may be performed to assess toxicity levels for normal and malignant cells. Concentrations from about 1 to 100 μg/ml per 10 5 cells may be employed to advantage. For n vivo use, the antisense oligonucleotides may be combined with a pharmaceutical carrier, such as a suitable liquid vehicle or excipient and an optional auxiliary additive or additives. The liquid vehicles and excipients are conventional and commercially available. Illustrative thereof are distilled water, physiological saline, aqueous solutions of dextrose, and the like. For in vivo cancer therapies, the antisense sequences preferably are provided directly to the malignant cells, as by injection to the neoplasm locus. Alternatively, the oligonucletide may be administered systemically, provided that the antisense sequence is associated with means for directing the sequences to the target malignant cells. In addition to administration with conventional carriers, the antisense oligonucleotides may be administered by a variety of specialized oligonucleotide delivery techniques. For example, oligonucleotides maybe encapsulated in liposomes, as described in Maniatis et al., Mannino et al. (1988) BioTechnology (>:682, and Feigner et al. (1989) Bethesda Res. Lab. Focus 1:^1.. Reconstituted virus envelopes also have been successfully used to deliver RNA and DNA to cells. (see, for example, Arad et. al., (1986) Biochem. Biophy. Acta. 859, 88-94. ) For therapeutic use i vivo, the antisense oligonucleotides are provided in a therapeutically effective amount, e.g., an amount sufficient to inhibit target protein expression in malignant cells. The actual dosage administered may take into account whether the nature of the treatment is prophylactic or therapeutic in nature, the age, weight, health and sex of the patient, the route of adminis ration, the size and nature of the malignancy, as well as other factors. The daily dosage may range from about 0.01 to 1,000 mg per day. Greater or lesser amounts of oligonucleotide may be administered, as required. As will be appreciated by those skilled in the medical art, particularly the chemotherapeutic art, appropriate dose ranges for in vivo administration would be routine experimentation for a clinician. As a preliminary guideline, effective concentrations for iji vitro inhibition of the target molecule may be determined first, as described above. II.B PROTEIN INHIBITION In another embodiment, the cancer marker protein itself may be used as a target molecule. For example, a binding protein designed to bind the marker protein essentially irreversibly can be provided to the malignant cells e.g., by association with a ligand specific for the cell and known to be absorbed by the cell. Means for targeting molecules to particular cells and cell types are well described in the chemotherapeutic art. Binding proteins maybe obtained and tested as described in Section I.A above. For example, the binding portions of antibodies maybe used to advantage. Particularly useful are binding proteins identified with high affinity for the target protein, e.g., greater than about 10 9 M " l . Alternatively, the DNA encoding the binding protein may be provided to the target cell as part of an expressable gene to be expressed within the cell following the procedures used for gene therapy protocols well described in the art. (see, for example, U.S. Patent No. 4,497,796, and Gene Transfer, Vijay R. Baichwal, ed. , (1986). It is anticipated that the complexed INM protein will be disabled and can inhibit cell division thereby. As described above for antisense nucleotides, for in vivo use, suitable binding proteins may be combined with a suitable pharmaceutical carrier, such as physiological saline or other useful carriers well characterized in the medical art. The parmaceutical compositions may be provided directly to malignant cells, e.g., by direct injection, or may be provided syste ically, provided the binding protein is associated with means for targeting the protein to target cells. Finally, suitable dose ranges and cell toxicity levels may be assessed using standard dose range experiments. Therapeutically effective concentrations may range from 0.1-1,000 mg per day. As described above, actual dosages administered may vary depending, for example, on the nature of the malignanacy, the age, weight and health of the individual, as well as other factors. « II. EXEMPLIFICATION The following examples further describe the utility of MTl and MT2 as markers for abnormal cell types, and how the genetic sequences encoding MTl and MT2 proteins were isolated and characterized, including the current best mode for their cloning and characterization, without limiting the scope thereof. For example, INM protein expression in E. coli is described herein. However, other prokayrotic and eukaryotic cell expression systems also are contemplated for recombinant expression of the proteins described herein. Other useful hosts contemplated include Saccharomyces, the insect/baculovirus expression system, and mammalian cells such as xenogenic myeloma cells and the well-characterized Chinese hamster ovary cell lines. MTl As demonstrated below, MTl expression levels are enhanced significantly in a number of different malignant cell types, including malignant breast, colon, bladder, ovary, prostate and cervix cell types. Presented below are the results of a standard immunoassy (precision + 5%), performed as described herein and in PCT publication WO93/03497 on nuclear matrix (NM) preparations made from normal and malignant human tissue extracts and which were prepared essentially as described therein (in 8M urea, 2% β- mercaptoethanol, 2% Nonidet P-40 (detergent).) The 302.47 antibody was raised against a NM preparation from CaSki, a cultured cervical tumor cell line (American Type Culture Collection, ATCC, Rockville, MD). MTl:2-8 was raised against the cloned MTl protein. Both antibodies bind to epitopes on the protein encoded by Seq. ID No.l, as demonstrated using standard binding assays. As can be seen from the results presented below, MTl is significantly elevated in malignant bladder tissue. Blotting experiments also indicate MTl levels are elevated in other malignant tissues. TABLE I ng MT-1/ Sample Antibody Combination g tissue normal bladder 302.47/MTl:2-8 13,500 bladder cancer 302.47/MTl:2-8 32,000 Cloning The natural-sourced MTl protein first was separated from human cervical tumor cells essentially following the procedure of Penman and Fey described in U.S. Pat. Nos. 4,882,268 and 4,885,236. Cells from the human cervical tumor cell lines CaSki and ME180 (obtained from the American Tissue Culture Collection, ATCC, Rockville, MD) were grown to confluence and removed from flasks by trypsinization. Suspended cells were washed twice with phosphate buffered saline (PBS) and extracted with cytoskeletal buffer (CSK): 100 mM NaCl, 300 mM sucrose, 10 mM PIPES, 3 mM MgCl 2 , 1 mM EGTA, 0.5% Triton X-100, 1.2 mM PMSF for 1 min at 4°C, followed by extraction in cold RSB (reticulocyte suspension buffer)/double detergent buffer: 100 mM NaCl, 3 mM MgCl 2 , 10 mM Tris, pH 7.4, 1% Tween 40, 0.5% deoxycholate, 1.2 mM PMSF. Alternatively, cells were extracted twice with the RBS/double detergent buffer. The two extraction protocols produced very similar preparations. The extracted cells were digested for 30 min at room temperature in digestion buffer: 50mM NaCl, 300 mM sucrose, 0.5% Triton X-100, 10 mM PIPES (pH 6.8), 3 mM MgCl 2 , ImM EGTA, 1.2 mM PMSF, containing 100 μg of both RNase A and DNase I. Chromatin was extracted from the digested nuclei by the addition of 2 M ammonium sulfate to a final concentration of 0.25 M. The extracted nuclear matrix-intermediate filament (NM-IF) scaffolds then were sedimented at 3700 x g for 15 min. The resulting pellet then was resuspended in disassembly buffer: 8 M urea, 20 mM MES (pH 6.6), 1 mM EGTA, 1.2mM PMSF, 0.1 mM MgCl 2 , 1% 2-mercaptoethanol, and the pellet sonicated and dialyzed overnight with 3 changes of 2000 volumes of assembly buffer: 0.15 M KC1, 25 mM imidazole (pH 7.1), 5 mM MgCl 2 , 2 mM DTT, 0.125 mM EGTA, 0.2 mM PMSF. The dialysate then was centrifuged at 100k x g for 1 h and the NM proteins recovered from the supernatant. Alternatively, NM-IF scaffolds were extracted directly with E400 buffer: 0.4 M NaCl, 0.02 M Tris pH 7.5, 0.1 mM MC1 2 , 0.5% 2-mercaptoethanol, 1.2 mM PMSF, for 30 min at 4°C, as described by von Kries et al. (1991) Cell 64.:123-135. The intermediate filament-rich pellet then was removed after centrifugation for 90 min at 40K rpm in a Beckman 70.1 Ti rotor. The supernatant remaining is enriched in MTl protein with little cytokeratin contamination. MTl-specific antibodies were produced by standard procedures. Specifically, Balb/c by J mice (Jackson Laboratory, Bar Harbor, ME) were injected intraperitoneally with purified Caski NM protein every 2 weeks for a total of 16 weeks. The mice were injected with a single boost 4 days prior to sacrifice and removal of the spleen. Freund's complete adjuvant was used in the first injection, incomplete Freund's in the second injection; subsequent injections were made with saline. Spleen cells were fused with the SP2/0- Agl4 mouse myeloma line (ATCC, Rockville, MD) using the standard fusion methodologies well known in the art. Hybridomas producing antibodies that reacted with nuclear matrix proteins were cloned and grown as ascites. Antigen specificity was assessed both by immunoflourescence spectroscopy and Western blot analysis. The 302.47 antibody was used to screen an expression library as described below to isolate the MTl gene. The cDNA clones for MTl were obtained from a Lambda ZAP expression library (Stratagene, La Jolla, CA) . Library screening was carried out according to the manufacturer's instructions and using the MTl-speciifc antibody 302.47. Briefly, a single positive clone containing a 2.45 kb insert was identified and subcloned into pBluescript II vectors (Stratagene, La Jolla, CA) opened at the EcoRI and Xhol cloning sites. The resulting plasmid, pMTl, was sequenced directly and further subcloned to produce the MTl fusion protein (see below). The cDNA sequences were obtained using the standard dideoxy method described in the art. Double stranded sequencing was done utilizing the pMTl vector primed with appropriate primers according to manufacturer's instructions (Stratagene, La Jolla, CA) . Internal sequences were obtained using synthetic primers, created based on the identified sequence. The entire nucleotide sequence and predicted amino acid sequence for MTl are shown in Seq. ID No. 1. The cDNA clone retains a polyadenylation signal a putative initiation codon, a continuous open reading frame and codon utilization consistent with a human gene. The predicted amino acid sequence of MTl consists of 639 amino acids encoding a protein of 70.5 kD with a pi of 5.47. The primary structure, as predicted by the Chou- Fasman algorithm (Chou and Fasman, (1978) Adv. Enzymol. Relat. Areas Mol. Biol. 7_:145-148) , consists of 72% alpha helix of which 56% is extended helix. The primary structure of MTl, represented in Fig. 1, contains 27 proline residues which generally occur in pairs or triplets throughout the molecule. The proline distribution within the sequence is illustrated in Fig. IA, where diamonds represent the proline residues. Proline pairs and triplets are indicted by stacked diamonds. At the N terminus, a 40 amino acid stretch contains a cluster of 8 prolines (residues 42-81, Seq. ID No. 1) that occur as pairs separated by 3 or fewer amino acids. A similar proline-rich region occurs in the C terminus of MTl (residues 551-563) where 6 prolines occur in a 13 amino acid stretch. Both proline-rich regions likely lie on the protein surface, based on probability calculations determined by the technique of Emini et al. (1985) J. Virol. 5_5:836-839. The high proline density also may explain the anomalous apparent molecular weight of the protein as determined by SDS polyacrylamide gel electrophoresis. As described above, the predicted molecular weight for MTl, calculated from the amino acid sequence, is 70.1 kD. However, as described below, both the natural-sourced and recombinant protein migrate as a 90 kD protein on an SDS polyacrylamide gel. Alternatively, it is also possible that the molecular weight variation may result from some post- translational modification achievable in both prokaryotic and eukaryotic cells. Between the two proline-rich termini, MTl displays a sequence consistent with a region of extended alpha helix structure, indicated by the hatched structure in Fig. IB. The extended helix is interrupted in 4 places by short helix-distorting amino acid stretches that usually include a pair of proline residues. A preliminary hypothesis as to the structure of MTl based on these theoretical calculations is that the molecule consists of an extended rod that is bounded on either end by a globular, proline-rich domain. Analysis of all available sequence databases indicates that MTl has a novel sequence that bears no significant homology to any known protein. In addition, the sequence appears to lack any known, identifiable DNA binding motif such as the leucine zipper motif. The cloned MTl DNA was used to perform standard Northern blot analysis of total and poly A+ RNA from ME180 cells, using standard procedures and 15 μg RNA. After blotting and hybridization with 32 P-labelled pMTl DNA, a single mRNA band was detected in the poly A+ fraction. This band was not apparent in the total RNA lane after a 48 h exposure of the autoradiogram, indicating that the MTl message is a low abundance species. Northern blot analysis indicates that the MTl protein is translated from a single mRNA. Northern blot analysis also indicates that the MTl RNA includes approximately 500 bp 5' of the protein-coding sequence presented in Seq. ID No. 1. This upstream sequence may represent one or more untranslated sequences and/or may encode additional protein coding sequences. A fusion protein for MTl was obtained using the insert from the pMTl construct described above and in Seq. ID No. 1, and the pMAL expression system (New England Biolabs Inc., Beverly, MA). In this system the gene of interest (MTl) is cloned into the pMal-c vector (New England Biolabs Inc., Beverly, MA) and the vector transfected into E. coli and expressed to produce a fusion protein containing both the protein of interest and the maltose binding protein. The maltose binding protein allows the fusion protein to be selectively purified in the presence of maltose and can be subsequently cleaved by proteolytic clavage with Factor Xa to yield intact, recombinant MTl protein. Here, MTl cDNA was cloned into the pMAL-c vector such that the initiation AUG codon was directly continuous with the 5' terminus of the maltose binding protein. After proteolytic cleavage with factor Xa the resulting MTl fusion protein retains the complete amino acid sequence encoded by the MTl cDNA with no additional amino acids. All experimental details of the pMAL system were carried out according to the manufacturer's instructions. As described above, both the natural-sourced and recombinantly produced protein have an electrophoretic mobility consistent with an apparent molecular weight of about 90kD on SDS-PAGE. In addition, the pi of both proteins is equivalent (5.4) and consistent with the predicted pi as calculated from the amino acid sequence. Peptide mapping of both proteins by cleavage at cysteine residues with 2-nitro-5-thiocyanobenzoic acid (NTCB), following the method of Leto and Marchesi (1984) J. Biol. Chem. 259:4603-4049, yields equivalent peptide fragments which share the same MTl cross reactivity by Western blot analysis. Moreover, the number and size of the peptide fragments produced are consistent with those predicted from the proposed MTl amino acid sequence. MT2 Like MTl, MT2 expression levels are enhanced significantly in a variety of malignant cell types, as determined both by serum assays and tissue culture supernatant assays. In the assays described below, the antibodies used were raised against two different cervical tumor cell line NM preparations (ME-180 and CaSKi, ATTC, Rockville, MD.) The 100-series antibodies are those raised against the ME-180 immunogen; the 300- series antibodies are those raised against CaSKi-NM immunogen. Of the antibodies described below, 107.7 and 307.33 have been determined to bind specifically with the MT2 protein, and 302-18, 302-22 and 302-29 cross react with a protein closely associated with MT2 and which co-isolates with it. Dose response evaluation results of two antibody combinations are shown in Table II, below, using ME-180 cell culture supernatant as the antigen source. Each assay shows dose dependent detection of antigen in the tissue culture supernatant, demonstrating the ability of the assay to quantitate soluble interior nuclear matrix protein released from dying cells. Table II Antibody 107-7 solid phase, 302-29 soluble antibody, ME-180 supernatant Concentration of supernatant Antibody 107-7 solid phase, 307-33 soluble antibody, ME-180 supernatant. Concentration of supernatant Next, interior nuclear matrix protein quantification was tested in supernatant from a variety of dying tumor tissues. Here, tumor and normal tissues were allowed to die in media by serum deprivation. Specifically, cell lines were grown to confluency in tissue culture flasks by standard culturing techniques. The media then was replaced with serum-free media and the cells placed in a 37°C incubator with 5% C0 2 for 7 to 14 days. At the end of the incubation the media was collected and centrifuged at 14,000xg to remove cellular debris. Supernatants were assayed in various configurations of sandwich assays. The results are shown in Fig. 3, where all values are in units/gm, using ME-180 antigen as standard. As can be seen from Fig. 3, MT2 antigen is released from each of the dying tissues and the increased cell death in tumor tissue is reflected in a higher MT2 average antigen value quantitated in cancer tissue versus normal tissue. Figure 4 shows the results of an analogous experiment performed using serum samples from cancer patients and normal blood donors. Here tissue is prepared as follows. Tissue is removed from a donor, flash frozen in liquid nitrogen within lOmin to 4hrs after removal and stored at -70°c until required. When ready to be used, the tissue is chopped into 0.1 to 0.3 cm cubes as it thaws using aseptic techniques in a laminar flow hood and placed in a T150 flask containing serum free media containing Fungizone and gentamycin. In general, 2-4g of tissue are used per 100ml media in the T150 flask. The flask containing the tissue then is incubated for 4-7 days at 37°c with 5% CO-,. After incubation the media is collected from the flasks. centrifuged at 14,000xg for 20min. As for Fig. 3, ME- 180 cell antigen was the standard. Results are reported in units/ml. A control experiment diluting supernatant antigen into serum and then quantitating the protein in solution indicates that serum has little or no effect on the assay. As can be seen in the results presented in Fig. 4, like the results shown in Fig. 3, serum samples from cancer patients reflect a higher rate of cell death as indicated by the quantifiably higher levels of MT2 antigen detected in these samples compared with those detected in the normal blood serum samples. Cloning Following the same general procedure as for MTl, a composition selectively enriched for MT2 was obtained from ME-180 cells (cervical carcinoma cells, from ATCC, Rockville, MD), and MT2-specific antibodies prepared. The 107.7 antibody was used to obtained a partial cDNA clone for MT2, by screening a lambda ZAP expression library, as for MT-1. The partial clone retrieved then was subcloned into a pBluescript II vector (pMT2) and the MT2 cDNA sequenced using standard techniques. The sequenced DNA, which corresponds to residues 1366 to 2865 of Seq. ID No. 3, then was analyzed to determine the reading frame and encoded amino acid-sequence. The complete coding sequence subsequently was determined and is presented in Seq. ID No. 3. (Compton et al. (1992) J. Cell Biol. 116: 1395-1408). The nucleotide sequence and predicted amino acid sequence for MT2 are described in Seq. ID No. 3. The primary structure of MT2 is represented schematically in Fig. 2: The protein appears to comprise at least 6 helical regions separated by proline pairs, (See Fig. 4A and B. ) The primary structure may allow the protein to form a coiled-coil structure in solution. As for Fig. 3, prolines are indicated by diamonds and helices by hatched boxes. In addition, both the N and C termini of MT2 appear to fold as globular domains (Compton et al. (1992) J. Cell Biol. 116: 1395-1408.) The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Matritech, Inc. (B) STREET: 763D Concord Ave (C) CITY: Cambridge (D) STATE: Massachusetts (E) COUNTRY: USA (F) POSTAL CODE (ZIP): 02138 (G) TELELPHONE: 1-617-661-6660 (H) TELEFAX: 1-617-661-8522 (I) TELEX: (ii) TITLE OF INVENTION: NOVEL MALIGNANT CELL TYPE MARKERS OF THE INTERIOR NUCLEAR MATRIX (iii) NUMBER OF SEQUENCES: 6 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: TESTA HURUITZ & THIBEAULT (B) STREET: 53 STATE STREET (C) CITY: BOSTON (D) STATE: MA (E) COUNTRY: USA (F) ZIP: 02109 (v) COMPUTER READABLE FORM: (A) HEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: PITCHER ESQ, EDMUND R (B) REGISTRATION NUMBER: 27,829 (C) REFERENCE/DOCKET NUMBER: MTP-013 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 617/248-7000 (B) TELEFAX: 617/248-7100 (2) INFORMATION FOR SEQ ID N0:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2360 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISH: HOMO SAPIENS (F) TISSUE TYPE: CERVIX TUMOR GAGATGGTTC TTGGTCCTGC AGCTTATAAT GTTCCATTGC CAAAGAAATC GATTCAGTCG 60 GGTCCACTAA AAATCTCTAG TGTATCAGAA GTA ATG AAA GAA TCT AAA CAG CCT 114 Met Lys Glu Ser Lys Gin Pro 1 5 GCC TCA CAA CTC CAA AAA CAA AAG GGA GAT ACT CCA GCT TCA GCA ACA 162 Ala Ser Gin Leu Gin Lys Gin Lys Gly Asp Thr Pro Ala Ser Ala Thr 10 15 20 GCA CCT ACA GAA GCG GCT CAA ATT ATT TCT GCA GCA GGT GAT ACC CTG 210 Ala Pro Thr Glu Ala Ala Gin He He Ser Ala Ala Gly Asp Thr Leu 25 30 35 TCG GTC CCA GCC CCT GCA GTT CAG CCT GAG GAA TCT TTA AAA ACT GAT 258 Ser Val Pro Ala Pro Ala Val Gin Pro Glu Glu Ser Leu Lys Thr Asp 40 45 50 55 CAC CCT GAA ATT GGT GAA GGA AAA CCC ACA CCT GCA CTT TCA GAA GCA 306 His Pro Glu He Gly Glu Gly Lys Pro Thr ?τo Ala Leu Ser Glu Ala 60 65 70 TCC TCA TCT TCT ATA AGG GAG CGA CCA CCT GAA GAA GTT GCA GCT CGC 354 Ser Ser Ser Ser He Arg Glu Arg Pro Pro Glu Glu Val Ala Ala Arg 75 80 85 CTT GCA CAA CAG GAA AAA CAA GAA CAA GTT AAA ATT GAG TCT CTA GCC 402 Leu Ala Gin Gin Glu Lys Gin Glu Gin Val Lys He Glu Ser Leu Ala 90 95 100 AAG AGC TTA GAA GAT GCT CTG AGG CAA ACT GCA AGT GTC ACT CTG CAG 450 Lys Ser Leu Glu Asp Ala Leu Arg Gin Thr Ala Ser Val Thr Leu Gin 105 110 115 GCT ATT GCA GCT CAG AAT GCT GCG GTC CAG GCT GTC AAT GCA CAC TCC 498 Ala He Ala Ala Gin Asn Ala Ala Val Gin Ala Val Asn Ala His Ser 120 125 130 135 AAC ATA TTG AAA GCC GCC ATG GAC AAT TCT GAG ATT GCA GGC GAG AAG 546 Asn He Leu Lys Ala Ala Met Asp Asn Ser Glu He Ala Gly Glu Lys 140 145 150 AAA TCT GCT CAG TGG CGC ACA GTG GAG GGT GCA TTG AAG GAA CGC AGA 594 Lys Ser Ala Gin Trp Arg Thr Val Glu Gly Ala Leu Lys Glu Arg Arg 155 160 165 AAG GCA GTA GAT GAA GCT GCC- GAT GCC CTT CTC AAA GCC AAA GAA GAG 642 Lys Ala Val Asp Glu Ala Ala Asp Ala Leu Leu Lys Ala Lys Glu Glu 170 175 180 TTA GAG AAG ATG AAA AGT GTG ATT GAA AAT GCA AAG AAA AAA GAG GTT 690 Leu Glu Lys Met Lys Ser Val He Glu Asn Ala Lys Lys Lys Glu Val 185 190 195 GCT GGG GCC AAG CCT CAT ATA ACT GCT GCA GAG GGT AAA CTT CAC AAC 738 Ala Gly Ala Lys Pro His He Thr Ala Ala Glu Gly Lys Leu His Asn 200 205 210 215 ATG ATA GTT GAT CTG GAT AAT GTG GTC AAA AAG GTC CAA GCA GCT CAG 786 Met He Val Asp Leu Asp Asn Val Val Lys Lys Val Gin Ala Ala Gin 220 225 230 TCT GAG GCT AAG GTT GTA TCT CAG TAT CAT GAG CTG GTG GTC CAA GCT 834 Ser Glu Ala Lys Val Val Ser Gin Tyr His Glu Leu Val Val Gin Ala 235 240 245 CGG GAT GAC TTT AAA CGA GAG CTG GAC AGT ATT ACT CCA GAA GTC CTT 882 Arg Asp Asp Phe Lys Arg Glu Leu Asp Ser He Thr Pro Glu Val Leu 250 255 260 CCT GGG TGG AAA GGA ATG AGT GTT TCA GAC TTA GCT GAC AAG CTC TCT 930 Pro Gly Trp Lys Gly Met Ser Val Ser Asp Leu Ala Asp Lys Leu Ser 265 270 275 ACT GAT GAT CTG AAC TCC CTC ATT GCT CAT GCA CAT CGT CGT ATT GAT 978 Thr Asp Asp Leu Asn Ser Leu He Ala His Ala His Arg Arg He Asp 280 285 290 295 CAG CTG AAC AGA GAG CTG GCA GAA CAG AAG GCC ACC GAA AAG CAG CAC 1026 Gin Leu Asn Arg Glu Leu Ala Glu Gin Lys Ala Thr Glu Lys Gin His 300 305 310 ATC ACG TTA GCC TTG GAG AAA CAA AAG CTG GAA GAA AAG CGG GCA TTT 1074 He Thr Leu Ala Leu Glu Lys Gin Lys Leu Glu Glu Lys Arg Ala Phe 315 320 325 GAC TCT GCA GTA GCA AAA GCA TTA GAA CAT CAC AGA AGT GAA ATA CAG 1122 Asp Ser Ala Val Ala Lys Ala Leu Glu His His Arg Ser Glu He Gin 330 335 340 GCT GAA CAG GAC AGA AAG ATA GAA GAA GTC AGA GAT GCC ATG GAA AAT 1170 Ala Glu Gin Asp Arg Lys He Glu Glu Val Arg Asp Ala Met Glu Asn 345 350 355 GAA ATG AGA ACC CCT TCG CCG ACA GCA GCT GCC CAC ACT GAT CAC TTG 1218 Glu Met Arg Thr Pro Ser Pro Thr Ala Ala Ala His Thr Asp His Leu 360 365 370 375 CGA GAT GTC CTT AGG GTA CAA GAA CAG GAA TTG AAG TCT GAA TTT GAG 1266 Arg Asp Val Leu Arg Val Gin Glu Gin Glu Leu Lys Ser Glu Phe Glu 380 385 390 CAG AAC CTG TCT GAG AAA CTC TCT GAA CAA GAA TTA CAA TTT CGT CGT 1314 Gin Asn Leu Ser Glu Lys Leu Ser Glu Gin Glu Leu Gin Phe Arg Arg \95 400 405 CTC AGT CAA GAG CAA GTT GAC AAC TTT ACT CTG GAT ATA AAT ACT GCC 1362 Leu Ser Gin Glu Gin Val Asp Asn Phe Thr Leu Asp He Asn Thr Ala 410 415 420 TAT GCC AGA CTC AGA GGA ATC GAA CAG GCT GTT CAG AGC CAT GCA GTT 1410 Tyr Ala Arg Leu Arg Gly He Glu Gin Ala Val Gin Ser His Ala Val 425 430 435 GCT GAA GAG GAA GCC AGA AAA GCC CAC CAA CTC TGG CTT TCA GTG GAG 1458 Ala Glu Glu Glu Ala Arg Lys Ala His Gin Leu Trp Leu Ser Val Glu 440 445 450 455 GCA TTA AAG TAC AGC ATG AAG ACC TCA TCT GCA GAA ACA CCT ACT ATC 1506 Ala Leu Lys Tyr Ser Met Lys Thr Ser Ser Ala Glu Thr Pro Thr He 460 465 470 CCG CTG GGT AGT GCG GTT GAG GCC ATC AAA GCC AAC TGT TCT GAT AAT 1554 Pro Leu Gly Ser Ala Val Glu Ala He Lys Ala Asn Cys Ser Asp Asn 475 480 485 GAA TTC ACC CAA GCT TTA ACC GCA GCT ATC CCT CCA GAG TCC CTG ACC 1602 Glu Phe Thr Gin Ala Leu Thr Ala Ala He Pro Pro Glu Ser Leu Thr 490 495 500 CGT GGG GTG TAC AGT GAA GAG ACC CTT AGA GCC CGT TTC TAT GCT GTT 1650 Arg Gly Val Tyr Ser Glu Glu Thr Leu Arg Ala Arg Phe Tyr Ala Val 505 510 515 CAA AAA CTG GCC CGA AGG GTA GCA ATG ATT GAT GAA ACC AGA AAT AGC 1698 Gin Lys Leu Ala Arg Arg Val Ala Met He Asp Glu Thr Arg Asn Ser 520 525 530 535 TTG TAC CAG TAC TTC CTC TCC TAC CTA CAG TCC CTG CTC CTA TTC CCA 1746 Leu Tyr Gin Tyr Phe Leu Ser Tyr Leu Gin Ser Leu Leu Leu Phe Pro 540 545 550 CCT CAG CAA CTG AAG CCG CCC CCA GAG CTC TGC CCT GAG GAT ATA AAC 1794 Pro Gin Gin Leu Lys Pro Pro Pro Glu Leu Cys Pro Glu Asp He Asn 555 560 565 ACA TTT AAA TTA CTG TCA TAT GCT TCC TAT TGC ATT GAG CAT GGT GAT 1842 Thr Phe Lys Leu Leu Ser Tyr Ala Ser Tyr Cys He Glu His Gly Asp 570 575 580 CTG GAG CTA GCA GCA AAG TTT GTC AAT CAG CTG AAG GGG GAA TCC AGA 1890 Leu Glu Leu Ala Ala Lys Phe Val Asn Gin Leu Lys Gly Glu Ser Arg 585 590 595 CGA GTG GCA CAG GAC TGG CTG AAG GAA GCC CGA ATG ACC CTA GAA ACG 1938 Arg Val Ala Gin Asp Trp Leu Lys Glu Ala Arg Met Thr Leu Glu Thr 600 605 610 615 AAA CAG ATA GTG GAA ATC CTG ACA GCA TAT GCC AGC GCC GTA GGA ATA 1986 Lys Gin He Val Glu He Leu Thr Ala Tyr Ala Ser Ala Val Gly He 620 625 630 GGA ACC ACT CAG GTG CAG CCA GAG TGAGGTTTAG GAAGATTTTC ATAAAGTCAT 2040 Gly Thr Thr Gin Val Gin Pro Glu 635 ATTTCATGTC AAAGGAAATC AGCAGTGATA GATGAAGGGT TCGCAGCGAG AGTCCCGGAC 2100 TTGTCTAGAA ATGAGCAGGT TTACAAGTAC TGTTCTAAAT GTTAACACCT GTTGCATTTA 2160 TATTCTTTCC ATTTGCTATC ATGTCAGTGA ACGCCAGGAG TGCTTTCTTT GCAACTTGTG 2220 TAACATTTTC TGTTTTTTCA GGTTTTACTG ATGAGGCTTG TGAGGCCAAT CAAAATAATG 2280 TTTGTGATCT CTACTACTGT TGATTTTGCC CTCGGAGCAA ACTGAATAAA GCAACAAGAT 2340 GAAAAAAAAA AAAAAAAAAA ___ 2360 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 639 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Lys Glu Ser Lys Gin Pro Ala Ser Gin Leu Gin Lys Gin Lys Gly 1 5 10 15 Asp Thr Pro Ala Ser Ala Thr Ala Pro Thr Glu Ala Ala Gin He He 20 25 30 Ser Ala Ala Gly Asp Thr Leu Ser Val Pro Ala Pro Ala Val Gin Pro 35 40 45 Glu Glu Ser Leu Lys Thr Asp His Pro Glu He Gly Glu Gly Lys Pro 50 55 60 Thr Pro Ala Leu Ser Glu Ala Ser Ser Ser Ser He Arg Glu Arg Pro 65 70 75 80 Pro Glu Glu Val Ala Ala Arg Leu Ala Gin Gin Glu Lys Gin Glu Gin 85 90 95 Val Lys He Glu Ser Leu Ala Lys Ser Leu Glu Asp Ala Leu Arg Gin 100 105 110 Thr Ala Ser Val Thr Leu Gin Ala He Ala Ala Gin Asn Ala Ala Val 115 120 125 Gin Ala Val Asn Ala His Ser Asn He Leu Lys Ala Ala Met Asp Asn 130 135 140 Ser Glu He Ala Gly Glu Lys Lys Ser Ala Gin Trp Arg Thr Val Glu 145 150 155 160 Gly Ala Leu Lys Glu Arg Arg Lys Ala Val Asp Glu Ala Ala Asp Ala 165 170 175 Leu Leu Lys Ala Lys Glu Glu Leu Glu Lys Met Lys Ser Val He Glu 180 185 190 Asn Ala Lys Lys Lys Glu Val Ala Gly Ala Lys Pro His He Thr Ala 195 200 205 Ala Glu Gly Lys Leu His Asn Met He Val Asp Leu Asp Asn Val Val 210 215 220 Lys Lys Val Gin Ala Ala Gin Ser Glu Ala Lys Val Val Ser Gin Tyr 225 230 235 240 His Glu Leu Val Val Gin Ala Arg Asp Asp Phe Lys Arg Glu Leu Asp 245 250 255 Ser He Thr Pro Glu Val Leu Pro Gly Trp Lys Gly Met Ser Val Ser 260 265 270 Asp Leu Ala Asp Lys Leu Ser Thr Asp Asp Leu Asn Ser Leu He Ala 275 280 285 His Ala His Arg Arg He Asp Gin Leu Asn Arg Glu Leu Ala Glu Gin 290 295 300 Lys Ala Thr Glu Lys Gin His He Thr Leu Ala Leu Glu Lys Gin Lys 305 310 315 320 Leu Glu Glu Lys Arg Ala Phe Asp Ser Ala Val Ala Lys Ala Leu Glu 325 330 335 His His Arg Ser Glu He Gin Ala Glu Gin Asp Arg Lys He Glu Glu 340 345 350 Val Arg Asp Ala Met Glu Asn Glu Met Arg Thr Pro Ser Pro Thr Ala 355 360 365 Ala Ala His Thr Asp His Leu Arg Asp Val Leu Arg Val Gin Glu Gin 370 375 380 Glu Leu Lys Ser Glu Phe Glu Gin Asn Leu Ser Glu Lys Leu Ser Glu 385 390 395 400 Gin Glu Leu Gin Phe Arg Arg Leu Ser Gin Glu Gin Val Asp Asn Phe 405 410 415 Thr Leu Asp He Asn Thr Ala Tyr Ala Arg Leu Arg Gly He Glu Gin 420 425 430 Ala Val Gin Ser His Ala Val Ala Glu Glu Glu Ala Arg Lys Ala His 435 440 445 Gin Leu Trp Leu Ser Val Glu Ala Leu Lys Tyr Ser Met Lys Thr Ser 450 455 460 Ser Ala Glu Thr Pro Thr He Pro Leu Gly Ser Ala Val Glu Ala He 465 470 475 480 Lys Ala Asn Cys Ser Asp Asn Glu Phe Thr Gin Ala Leu Thr Ala Ala 485 490 495 He Pro Pro Glu Ser Leu Thr Arg Gly Val Tyr Ser Glu Glu Thr Leu 500 505 510 Arg Ala Arg Phe Tyr Ala Val Gin Lys Leu Ala Arg Arg Val Ala Met 515 520 525 He Asp Glu Thr Arg Asn Ser Leu Tyr Gin Tyr Phe Leu Ser Tyr Leu 530 535 540 Gin Ser Leu Leu Leu Phe Pro Pro Gin Gin Leu Lys Pro Pro Pro Glu 545 550 555 560 Leu Cys Pro Glu Asp He Asn Thr Phe Lys Leu Leu Ser Tyr Ala Ser 565 570 575 Tyr Cys He Glu His Gly Asp Leu Glu Leu Ala Ala Lys Phe Val Asn 580 585 590 Gin Leu Lys Gly Glu Ser Arg Arg Val Ala Gin Asp Trp Leu Lys Glu 595 600 605 Ala Arg Met Thr Leu Glu Thr Lys Gin He Val Glu He Leu Thr Ala 610 615 620 Tyr Ala Ser Ala Val Gly He Gly Thr Thr Gin Val Gin Pro Glu 625 630 635 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6306 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..6306 (x) PUBLICATION INFORMATION: (A) AUTHORS: COMPTON, DUANE A; SZILAK, ILYA; CLEVELAND, DON W. (B) PRIMARY STRUCTURE OF NUMA... (C) JOURNAL: Journal of Cell Biology (D) VOLUME: 116 (E) RELEVANT RESIDUES IN SEQ ID NO:3: FROM 1 TO 6306 (F) PAGES: 1395-1408 (G) DATE: MAR - 1992 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: ATG ACA CTC CAC GCC ACC CGG GGG GCT GCA CTC CTC TCT TGG GTG AAC 48 Met Thr Leu His Ala Thr Arg Gly Ala Ala Leu Leu Ser Trp Val Asn 1 5 10 15 AGT CTA CAC GTG GCT GAC CCT GTG GAG GCT GTG CTG CAG CTC CAG GAC 96 Ser Leu His Val Ala Asp Pro Val Glu Ala Val Leu Gin Leu Gin Asp 20 25 30 TGC AGC ATC TTC ATC AAG ATC ATT GAC AGA ATC CAT GGC ACT GAA GAG 144 Cys Ser He Phe He Lys He He Asp Arg He His Gly Thr Glu Glu 35 40 45 GGA CAG CAA ATC TTG AAG CAG CCG GTG TCA GAG AGA CTG GAC TTT GTG 192 Gly Gin Gin He Leu Lys Gin Pro Val Ser Glu Arg Leu Asp Phe Val 50 55 60 TGC AGT TTT CTG CAG AAA AAT CGA AAA CAT CCC TCT TCC CCA GAA TGC 240 Cys Ser Phe Leu Gin Lys Asn Arg Lys His Pro Ser Ser Pro Glu Cys 65 70 75 80 CTG GTA TCT GCA CAG AAG GTG CTA GAG GGA TCA GAG CTG GAA CTG GCG 288 Leu Val Ser Ala Gin Lys Val Leu Glu Gly Ser Glu Leu Glu Leu Ala 85 90 95 AAG ATG ACC ATG CTG CTC TTA TAC CAC TCT ACC ATG AGC TCC AAA AGT 336 Lys Met Thr Met Leu Leu Leu Tyr His Ser Thr Met Ser Ser Lys Ser 100 105 110 CCC AGG GAC TGG GAA CAG TTT GAA TAT AAA ATT CAG GCT GAG TTG GCT 384 Pro Arg Asp Trp Glu Gin Phe Glu Tyr Lys He Gin Ala Glu Leu Ala 115 120 125 GTC ATT CTT AAA TTT GTG CTG GAC CAT GAG GAC GGG CTA AAC CTT AAT 432 Val He Leu Lys Phe Val Leu Asp His Glu Asp Gly Leu Asn Leu Asn 130 135 140 GAG GAC CTA GAG AAC TTC CTA CAG AAA GCT CCT GTG CCT TCT ACC TGT 480 Glu Asp Leu Glu Asn Phe Leu Gin Lys Ala Pro Val Pro Ser Thr Cys 145 150 155 160 TCT AGC ACA TTC CCT GAA GAG CTC TCC CCA CCT AGC CAC CAG GCC AAG 528 Ser Ser Thr Phe Pro Glu Glu Leu Ser Pro Pro Ser His Gin Ala Lys 165 170 175 AGG GAG ATT CGC TTC CTA GAG CTA CAG AAG GTT GCC TCC TCT TCC AGT 576 Arg Glu He Arg Phe Leu Glu Leu Gin Lys Val Ala Ser Ser Ser Ser 180 185 190 GGG AAC AAC TTT CTC TCA GGT TCT CCA GCT TCT CCC ATG GGT GAT ATC 624 Gly Asn Asn Phe Leu Ser Gly Ser Pro Ala Ser Pro Met Gly Asp He 195 200 205 CTG CAG ACC CCA CAG TTC CAG ATG AGA CGG CTG AAG AAG CAG CTT GCT 672 Leu Gin Thr Pro Gin Phe Gin Met Arg Arg Leu Lys Lys Gin Leu Ala 210 215 220 GAT GAG AGA AGT AAT AGG GAT GAG CTG GAG CTG GAG CTA GCT GAG AAC 720 Asp Glu Arg Ser Asn Arg Asp Glu Leu Glu Leu Glu Leu Ala Glu Asn 225 230 235 240 CGC AAG CTC CTC ACC GAG AAG GAT GCA CAG ATA GCC ATG ATG CAG CAG 768 Arg Lys Leu Leu Thr Glu Lys Asp Ala Gin He Ala Met Met Gin Gin 245 250 255 CGC ATT GAC CGC CTA GCC CTG CTG AAT GAG AAG CAG GCG GCC AGC CCA 816 Arg He Asp Arg Leu Ala Leu Leu Asn Glu Lys Gin Ala Ala Ser Pro 260 265 270 CTG GAG CCC AAG GAG CTT GAG GAG CTG CGT GAC AAG AAT GAG AGC CTT 864 Leu Glu Pro Lys Glu Leu Glu Glu Leu Arg Asp Lys Asn Glu Ser Leu 275 280 285 ACC ATG CGG CTG CAT GAA ACC CTG AAG CAG TGC CAG GAC CTG AAG ACA 912 Thr Met Arg Leu His Glu Thr Leu Lys Gin Cys Gin Asp Leu Lys Thr 290 295 300 GAG AAG AGC CAG ATG GAT CGC AAA ATC AAC CAG CTT TCG GAG GAG AAT 960 Glu Lys Ser Gin Met Asp Arg Lys He Asn Gin Leu Ser Glu Glu Asn 305 310 315 320 GGA GAC CTT TCC TTT AAG CTG CGG GAG TTT GCC AGT CAT CTG CAG CAG 1008 Gly Asp Leu Ser Phe Lys Leu Arg Glu Phe Ala Ser His Leu Gin Gin 325 330 335 CTA CAG GAT GCC CTC AAT GAG CTG ACG GAG GAG CAC AGC AAG GCC ACT 1056 Leu Gin Asp Ala Leu Asn Glu Leu Thr Glu Glu His Ser Lys Ala Thr 340 345 350 CAG GAG TGG CTA GAG AAG CAG GCC CAG CTG GAG AAG GAG CTC AGC GCA 1104 Gin Glu Trp Leu Glu Lys Gin Ala Gin Leu Glu Lys Glu Leu Ser Ala 355 360 365 GCC CTG CAG GAC AAG AAA TGC CTT GAA GAG AAG AAC GAA ATC CTT CAG 1152 Ala Leu Gin Asp Lys Lys Cys Leu Glu Glu Lys Asn Glu He Leu Gin 370 375 380 GGA AAA CTT TCA CAG CTG GAA GAA CAC TTG TCC CAG CTG CAG GAT AAC 1200 Gly Lys Leu Ser Gin Leu Glu Glu His Leu Ser Gin Leu Gin Asp Asn 385 390 395 400 CCA CCC CAG GAG AAG GGC GAG GTG CTG GGT GAT GTC TTG CAG CTG GAA 1248 Pro Pro Gin Glu Lys Gly Glu Val Leu Gly Asp Val Leu Gin Leu Glu 405 410 415 ACC TTG AAG CAA GAG GCA GCC ACT CTT GCT GCA AAC AAC ACA CAG CTC 1296 Thr Leu Lys Gin Glu Ala Ala Thr Leu Ala Ala Asn Asn Thr Gin Leu 420 425 430 CAA GCC AGG GTA GAG ATG CTG GAG ACT GAG CGA GGC CAG CAG GAA GCC 1344 Gin Ala Arg Val Glu Met Leu Glu Thr Glu Arg Gly Gin Gin Glu Ala 435 440 445 AAG CTG CTT GCT GAG CGG GGC CAC TTC GAA GAA GAA AAG CAG CAG CTG 1392 Lys Leu Leu Ala Glu Arg Gly His Phe Glu Glu Glu Lys Gin Gin Leu 450 455 460 TCT AGC CTG ATC ACT GAC CTG CAG AGC TCC ATC TCC AAC CTC AGC CAG 1440 Ser Ser Leu He Thr Asp Leu Gin Ser Ser He Ser Asn Leu Ser Gin 465 470 475 480 GCC AAG GAA GAG CTG GAG CAG GCC TCC CAG GCT CAT GGG GCC CGG TTG 1488 Ala Lys Glu Glu Leu Glu Gin Ala Ser Gin Ala His Gly Ala Arg Leu 485 490 495 ACT GCC CAG GTG GCC TCT CTG ACC TCT GAG CTC ACC ACA CTC AAT GCC 1536 Thr Ala Gin Val Ala Ser Leu Thr Ser Glu Leu Thr Thr Leu Asn Ala 500 505 510 ACC ATC CAG CAA CAG GAT CAA GAA CTG GCT GGC CTG AAG CAG CAG GCC 1584 Thr He Gin Gin Gin Asp Gin Glu Leu Ala Gly Leu Lys Gin Gin Ala 515 520 525 AAA GAG AAG CAG GCC CAG CTA GCA CAG ACC CTC CAA CAG CAA GAA CAG 1632 Lys Glu Lys Gin Ala Gin Leu Ala Gin Thr Leu Gin Gin Gin Glu Gin 530 535 540 GCC TCC CAG GGC CTC CGC CAC CAG GTG GAG CAG CTA AGC AGT AGC CTG 1680 Ala Ser Gin Gly Leu Arg His Gin Val Glu Gin Leu Ser Ser Ser Leu 545 550 555 560 AAG CAG AAG GAG CAG CAG TTG AAG GAG GTA GCG GAG AAG CAG GAG GCA 1728 Lys Gin Lys Glu Gin Gin Leu Lys Glu Val Ala Glu Lys Gin Glu Ala 565 570 575 ACT AGG CAG GAC CAT GCC CAG CAA CTG GCC ACT GCT GCA GAG GAG CGA 1776 Thr Arg Gin Asp His Ala Gin Gin Leu Ala Thr Ala Ala Glu Glu Arg 580 585 590 GAG GCC TCC TTA AGG GAG CGG GAT GCG GCT CTC AAG CAG CTG GAG GCA 1824 Glu Ala Ser Leu Arg Glu Arg Asp Ala Ala Leu Lys Gin Leu Glu Ala 595 600 . 605 CTG GAG AAG GAG AAG GCT GCC AAG CTG GAG ATT CTG CAG CAG CAA CTT 1872 Leu Glu Lys Glu Lys Ala Ala Lys Leu Glu He Leu Gin Gin Gin Leu 610 615 620 CAG GTG GCT AAT GAA GCC CGG GAC AGT GCC CAG ACC TCA GTG ACA CAG 1920 Gin Val Ala Asn Glu Ala Arg Asp Ser Ala Gin Thr Ser Val Thr Gin 625 630 635 640 GCC CAG CGG GAG AAG GCA GAG CTG AGC CGG AAG GTG GAG GAA CTC CAG 1968 Ala Gin Arg Glu Lys Ala Glu Leu Ser Arg Lys Val Glu Glu Leu Gin 645 650 655 GCC TGT GTT GAG ACA GCC CGC CAG GAA CAG CAT GAG GCC CAG GCC CAG 2016 Ala Cys Val Glu Thr Ala Arg Gin Glu Gin His Glu Ala Gin Ala Gin 660 665 670 GTT GCA GAG CTA GAG TTG CAG CTG CGG TCT GAG CAG CAA AAA GCA ACT 2064 Val Ala Glu Leu Glu Leu Gin Leu Arg Ser Glu Gin Gin Lys Ala Thr 675 680 685 GAG AAA GAA AGG GTG GCC CAG GAG AAG GAC CAG CTC CAG GAG CAG CTC 2112 Glu Lys Glu Arg Val Ala Gin Glu Lys Asp Gin Leu Gin Glu Gin Leu 690 695 700 CAG GCC CTC AAA GAG TCC TTG AAG GTC ACC AAG GGC AGC CTT GAA GAG 2160 Gin Ala Leu Lys Glu Ser Leu Lys Val Thr Lys Gly Ser Leu Glu Glu 705 710 715 720 GAG AAG CGC AGG GCT GCA GAT GCC CTG GAA GAG CAG CAG CGT TGT ATC 2208 Glu Lys Arg Arg Ala Ala Asp Ala Leu Glu Glu Gin Gin Arg Cys He 725 730 735 TCT GAG CTG AAG GCA GAG ACC CGA AGC CTG GTG GAG CAG CAT AAG CGG 2256 Ser Glu Leu Lys Ala Glu Thr Arg Ser Leu Val Glu Gin His Lys Arg 740 745 750 GAA CGA AAG GAG CTG GAA GAA GAG AGG GCT GGG CGC AAG GGG CTG GAG 2304 Glu Arg Lys Glu Leu Glu Glu Glu Arg Ala Gly Arg Lys Gly Leu Glu 755 760 765 GCT CGA TTA CTG CAG CTT GGG GAG GCC CAT CAG GCT GAG ACT GAA GTC 2352 Ala Arg Leu Leu Gin Leu Gly Glu Ala His Gin Ala Glu Thr Glu Val 770 775 780 , CTG CGG CGG GAG CTG GCA GAG GCC ATG GCT GCC CAG CAC ACA GCT GAG 2400 Leu Arg Arg Glu Leu Ala Glu Ala Met Ala Ala Gin His Thr Ala Glu 785 790 795 800 AGT GAG TGT GAG CAG CTC GTC AAA GAA GTA GCT GCC TGG CGT GAC GGG 2448 Ser Glu Cys Glu Gin Leu Val Lys Glu Val Ala Ala Trp Arg Asp Gly 805 810 __ 815 TAT GAG GAT AGC CAG CAA GAG GAG GCA CAG TAT GGC GCC ATG TTC CAG 2496 Tyr Glu Asp Ser Gin Gin Glu Glu Ala Gin Tyr Gly Ala Met Phe Gin 820 825 830 GAA CAG CTG ATG ACT TTG AAG GAG GAA TGT GAG AAG GCC CGC CAG GAG 2544 Glu Gin Leu Met Thr Leu Lys Glu Glu Cys Glu Lys Ala Arg Gin Glu 835 840 845 CTG CAG GAG GCA AAG GAG AAG GTG GCA GGC ATA GAA TCC CAC AGC GAG 2592 Leu Gin Glu Ala Lys Glu Lys Val Ala Gly He Glu Ser His Ser Glu 850 855 860 CTC CAG ATA AGC CGG CAG CAG AAC AAA CTA GCT GAG CTC CAT GCC AAC 2640 Leu Gin He Ser Arg Gin Gin Asn Lys Leu Ala Glu Leu His Ala Asn 865 870 875 880 CTG GCC AGA GCA CTC CAG CAG GTC CAA GAG AAG GAA GTC AGG GCC CAG 2688 Leu Ala Arg Ala Leu Gin Gin Val Gin Glu Lys Glu Val Arg Ala Gin 885 890 895 AAG CTT GCA GAT GAC CTC TCC ACT CTG CAG GAA AAG ATG GCT GCC ACC 2736 Lys Leu Ala Asp Asp Leu Ser Thr Leu Gin Glu Lys Met Ala Ala Thr 900 905 910 AGC AAA GAG GTG GCC CGC TTG GAG ACC TTG GTC CGC .AAG GCA GGT GAG 2784 Ser Lys Glu Val Ala Arg Leu Glu Thr Leu Val Arg Lys Ala Gly Glu 915 920 925 CAG CAG GAA ACA GCC TCC CGG GAG TTA GTC AAG GAG CCT GCG AGG GCA 2832 Gin Gin Glu Thr Ala Ser Arg Glu Leu Val Lys Glu Pro Ala Arg Ala 930 935 940 GGA GAC AGA CAG CCC GAG TGG CTG GAA GAG CAA CAG GGA CGC CAG TTC 2880 Gly Asp Arg Gin Pro Glu Trp Leu Glu Glu Gin Gin Gly Arg Gin Phe 945 950 955 960 TGC AGC ACA CAG GCA GCG CTG CAG GCT ATG GAG CGG GAG GCA GAG CAG 2928 Cys Ser Thr Gin Ala Ala Leu Gin Ala Met Glu Arg Glu Ala Glu Gin 965 970 975 ATG GGC AAT GAG CTG GAA CGG CTG CGG GCC GCG CTG ATG GAG AGC CAG 2976 Met Gly Asn Glu Leu Glu Arg Leu Arg Ala Ala Leu Met Glu Ser Gin 980 985 990 GGG CAG CAG CAG GAG GAG CGT GGG CAG CAG GAA AGG GAG GTG GCG CGG 3024 Gly Gin Gin Gin Glu Glu Arg Gly Gin Gin Glu Arg Glu Val Ala Arg 995 1000 1005 CTG ACC CAG GAG CGG GGC CGT GCC CAG GCT GAC CTT GCC CTG GAG AAG 3072 Leu Thr Gin Glu Arg Gly Arg Ala Gin Ala Asp Leu Ala Leu Glu Lys 1010 1015 1020 GCG GCC AGA GCA GAG CTT GAG ATG CGG CTG CAG AAC GCC CTC AAC GAG 3120 Ala Ala Arg Ala Glu Leu Glu Met Arg Leu Gin Asn Ala Leu Asn Glu 1025 1030 1035 1040 CAG CGT GTG GAG TTC GCT ACC CTG CAA GAG GCA CTG GCT CAT GCC CTG 3168 Gin Arg Val Glu Phe Ala Thr Leu Gin Glu Ala Leu Ala His Ala Leu 1045 1050 1055 ACG GAA AAG GAA GGC AAG GAC CAG GAG TTG GCC AAG CTT CGT GGT CTG 3216 Thr Glu Lys Glu Gly Lys Asp Gin Glu Leu Ala Lys Leu Arg Gly Leu 1060 1065 1070 GAG GCA GCC CAG ATA AAA GAG CTG GAG GAA CTT CGG CAA ACC GTG AAG 3264 Glu Ala Ala Gin He Lys Glu Leu Glu Glu Leu Arg Gin Thr Val Lys 1075 1080 1085 CAA CTG AAG GAA CAG CTG GCT AAG AAA GAA AAG GAG CAC GCA TCT GGC 3312 Gin Leu Lys Glu Gin Leu Ala Lys Lys Glu Lys Glu His Ala Ser Gly 1090 1095 1100 TCA GGA GCC CAA TCT GAG GCT GCT GGC AGG ACA GAG CCA ACA GGC CCC 3360 Ser Gly Ala Gin Ser Glu Ala Ala Gly Arg Thr Glu Pro Thr Gly Pro 1105 1110 1115 1120 AAG CTG GAA GCA CTG CGG GCA GAG GTG AGC AAG CTG GAA CAG CAA TGC 3408 Lys Leu Glu Ala Leu Arg Ala Glu Val Ser Lys Leu Glu Gin Gin Cys 1125 1130 1135 CAG AAG CAG CAG GAG CAG GCT GAC AGC CTG GAA CGC AGC CTC GAG GCT 3456 Gin Lys Gin Gin Glu Gin Ala Asp Ser Leu Glu Arg Ser Leu Glu Ala 1140 1145 1150 GAG CGG GCC TCC CGG GCT GAG CGG GAC AGT GCT CTG GAG ACT CTG CAG 3504 Glu Arg Ala Ser Arg Ala Glu Arg Asp Ser Ala Leu Glu Thr Leu Gin 1155 1160 1165 GGC CAG TTA GAG GAG AAG GCC CAG GAG CTA GGG CAC AGT CAG AGT GCC 3552 Gly Gin Leu Glu Glu Lys Ala Gin Glu Leu Gly His Ser Gin Ser Ala 1170 1175 1180 TTA GCC TCG GCC CAA CGG GAG TTG GCT GCC TTC CGC ACC AAG GTA CAA 3600 Leu Ala Ser Ala Gin Arg Glu Leu Ala Ala Phe Arg Thr Lys Val Gin 1185 1190 1195 1200 GAC CAC AGC AAG GCT GAA GAT GAG TGG AAG GCC CAG GTG GCC CGG GGC 3648 Asp His Ser Lys Ala Glu Asp Glu Trp Lys Ala Gin Val Ala Arg Gly 1205 1210 1215 CGG CAA GAG GCT GAG AGG AAA AAT AGC CTC ATC AGC AGC TTG GAG GAG 3696 Arg Gin Glu Ala Glu Arg Lys Asn Ser Leu He Ser Ser Leu Glu Glu 1220 1225 1230 GAG GTG TCC ATC CTG AAT CGC CAG GTC CTG GAG AAG GAG GGG GAG AGC 3744 Glu Val Ser He Leu Asn Arg Gin Val Leu Glu Lys Glu Gly Glu Ser 1235 1240 1245 AAG GAG TTG AAG CGG CTG GTG ATG GCC GAG TCA GAG AAG AGC CAG AAG 3792 Lys Glu Leu Lys Arg Leu Val Met Ala Glu Ser Glu Lys Ser Gin Lys 1250 1255 1260 CTG GAG GAG AGC TGC GCC TGC TGC AGG CAG AGA CAG CCA GCA ACA GTG 3840 Leu Glu Glu Ser Cys Ala Cys Cys Arg Gin Arg Gin Pro Ala Thr Val 1265 1270 1275 1280 CCA GAG CTG CAG AAC GCA GCT CTG CTC TGC GGG AGG AGG TGC AGA GCC 3888 Pro Glu Leu Gin Asn Ala Ala Leu Leu Cys Gly Arg Arg Cys Arg Ala 1285 1290 1295 TCC GGG AGG GAG GCT GAG AAA CAG CGG GTG GCT TCA GAG AAC CTG CGG 3936 Ser Gly Arg Glu Ala Glu Lys Gin Arg Val Ala Ser Glu Asn Leu Arg 1300 1305 1310 CAG GAG CTG ACC TCA CAG GCT GAG CGT GCG GAG GAG CTG GGC CAA GAA 3984 Gin Glu Leu Thr Ser Gin Ala Glu Arg Ala Glu Glu Leu Gly Gin Glu 1315 1320 1325 TTG AAG GCG TGG CAG GAG AAG TTC TTC CAG AAA GAG CAG GCC CTC TCC 4032 Leu Lys Ala Trp Gin Glu Lys Phe Phe Gin Lys Glu Gin Ala Leu Ser 1330 1335 1340 ACC CTG CAG CTC GAG CAC ACC AGC ACA CAG GCC CTG GTG AGT GAG CTG 4080 Thr Leu Gin Leu Glu His Thr Ser Thr Gin Ala Leu Val Ser Glu Leu 1345 1350 1355 1360 CTG CCA GCT AAG CAC CTC TGC CAG CAG CTG CAG GCC GAG CAG GCC GCT 4128 Leu Pro Ala Lys His Leu Cys Gin Gin Leu Gin Ala Glu Gin Ala Ala 1365 1370 1375 GCC GAG AAA CGC CAC CGT GAG GAG CTG GAG CAG AGC AAG CAG GCC GCT 4176 Ala Glu Lys Arg His Arg Glu Glu Leu Glu Gin Ser Lys Gin Ala Ala 1380 1385 1390 GGG GGA CTG CGG GCA GAG CTG CTG CGG GCC CAG CGG GAG CTT GGG GAG 4224 Gly Gly Leu Arg Ala Glu Leu Leu Arg Ala Gin Arg Glu Leu Gly Glu 1395 1400 1405 CTG ATT CCT CTG CGG CAG AAG GTG GCA GAG CAG GAG CGA ACA GCT CAG 4272 Leu He Pro Leu Arg Gin Lys Val Ala Glu Gin Glu Arg Thr Ala Gin 1410 1415 1420 CAG CTG CGG GCA GAG AAG GCC AGC TAT GCA GAG CAG CTG AGC ATG CTG 4320 Gin Leu Arg Ala Glu Lys Ala Ser Tyr Ala Glu Gin Leu Ser Met Leu 1425 1430 1435 1440 AAG AAG GCG CAT GGC CTG CTG GCA GAG GAG AAC CGG GGG CTG GGT GAG 4368 Lys Lys Ala His Gly Leu Leu Ala Glu Glu Asn Arg Gly Leu Gly Glu 1445 1450 1455 CGG GCC AAC CTT GGC CGG CAG TTT CTG GAA GTG GAG TTG GAC CAG GCC 4416 Arg Ala Asn Leu Gly Arg Gin Phe Leu Glu Val Glu Leu Asp Gin Ala 1460 1465 1470 CGG GAA AAG TAT GTC CAA GAG TTG GCA GCC GTA CGT GCT GAT GCT GAG 4464 Arg Glu Lys Tyr Val Gin Glu Leu Ala Ala Val Arg Ala Asp Ala Glu 1475 1480 1485 ACC CGT CTG GCT GAG GTG CAG CGA GAA GCA CAG AGC ACT GCC CGG GAG 4512 Thr Arg Leu Ala Glu Val Gin Arg Glu Ala Gin Ser Thr Ala Arg Glu 1490 1495 1500 CTG GAG GTG ATG ACT GCC AAG TAT GAG GGT GCC AAG GTC AAG GTC CTG 4560 Leu Glu Val Met Thr Ala Lys Tyr Glu Gly Ala Lys Val Lys Val Leu 1505 1510 1515 1520 GAG GAG AGG CAG CGG TTC CAG GAA GAG AGG CAG AAA CTC ACT GCC CAG 4608 Glu Glu Arg Gin Arg Phe Gin Glu Glu Arg Gin Lys Leu Thr Ala Gin 1525 1530 1535 GTG GAA GAA CTG AGT AAG AAA CTG GCT GAC TCT GAC CAA GCC AGC AAG 4656 Val Glu Glu Leu Ser Lys Lys Leu Ala Asp Ser Asp Gin Ala Ser Lys 1540 1545 1550 GTG CAG CAG CAG AAG CTG AAG GCT GTC CAG GCT CAG GGA GGC GAG AGC 4704 Val Gin Gin Gin Lys Leu Lys Ala Val Gin Ala Gin Gly Gly Glu Ser 155^ 1560 1565 CAG CAG GAG GCC CAG CGC TTC CAG GCC CAG CTG AAT GAA CTG CAA GCC 4752 Gin Gin Glu Ala Gin Arg Phe Gin Ala Gin Leu Asn Glu Leu Gin Ala 1570 1575 1580 CAG TTG AGC CAG AAG GAG CAG GCA GCT GAG CAC TAT AAG CTG CAG ATG 4800 Gin Leu Ser Gin Lys Glu Gin Ala Ala Glu His Tyr Lys Leu Gin Met 1585 1590 1595 1600 GAG AAA GCC AAA ACA CAT TAT GAT GCC AAG AAG CAG CAG AAC CAA GAG 4848 Glu Lys Ala Lys Thr His Tyr Asp Ala Lys Lys Gin Gin Asn Gin Glu 1605 1610 1615 CTG CAG GAG CAG CTG CGG AGC CTG GAG CAG CTG CAG AAG GAA AAC AAA 4896 Leu Gin Glu Gin Leu Arg Ser Leu Glu Gin Leu Gin Lys Glu Asn Lys 1620 1625 1630 GAG CTG CGA GCT GAA GCT GAA CGG CTG GGC CAT GAG CTA CAG CAG GCT 4944 Glu Leu Arg Ala Glu Ala Glu Arg Leu Gly His Glu Leu Gin Gin Ala 1635 1640 1645 GGG CTG AAG ACC AAG GAG GCT GAA CAG ACC TGC CGC CAC CTT ACT GCC 4992 Gly Leu Lys Thr Lys Glu Ala Glu Gin Thr Cys Arg His Leu Thr Ala 1650 1655 1660 CAG GTG CGC AGC CTG GAG GCA CAG GTT GCC CAT GCA GAC CAG CAG CTT 5040 Gin Val Arg Ser Leu Glu Ala Gin Val Ala His Ala Asp Gin Gin Leu 1665 1670 1675 1680 CGA GAC CTG GGC AAA TTC CAG GTG GCA ACT GAT GCT TTA AAG AGC CGT 5088 Arg Asp Leu Gly Lys Phe Gin Val Ala Thr Asp Ala Leu Lys Ser Arg 1685 1690 1695 GAG CCC CAG GCT AAG CCC CAG CTG GAC TTG AGT ATT GAC AGC CTG GAT 5136 Glu Pro Gin Ala Lys Pro Gin Leu Asp Leu Ser He Asp Ser Leu Asp 1700 1705 1710 CTG AGC TGC GAG GAG GGG ACC CCA CTC AGT ATC ACC AGC AAG CTG CCT 5184 Leu Ser Cys Glu Glu Gly Thr Pro Leu Ser He Thr Ser Lys Leu Pro 1715 1720 1725 CGT ACC CAG CCA GAC GGC ACC AGC GTC CCT GGA GAA CCA GCC TCA CCT 5232 Arg Thr Gin Pro Asp Gly Thr Ser Val Pro Gly Glu Pro Ala Ser Pro 1730 1735 1740 ATC TCC CAG CGC CTG CCC CCC AAG GTA GAA TCC CTG GAG AGT CTC TAC 5280 He Ser Gin Arg Leu Pro Pro Lys Val Glu Ser Leu Glu Ser Leu Tyr 1745 1750 1755 1760 TTC ACT CCC ATC CCT GCT CGG AGT CAG GCC CCC CTG GAG AGC AGC CTG 5328 Phe Thr Pro He Pro Ala Arg Ser Gin Ala Pro Leu Glu Ser Ser Leu 1765 1770 1775 GAC TCC CTG GGA GAC GTC TTC CTG GAC TCG GGT CGT AAG ACC CGC TCC 5376 Asp Ser Leu Gly Asp Val Phe Leu Asp Ser Gly Arg Lys Thr Arg Ser 1780 1785 1790 GCT CGT CGG CGC ACC ACG CAG ATC ATC AAC ATC ACC ATG ACC AAG AAG 5424 Ala Arg Arg Arg Thr Thr Gin He He Asn He Thr Met Thr Lys Lys 1795 1800 1805 CTA GAT GTG GAA GAG CCA GAC AGC GCC AAC TCA TCG TTC TAC AGC ACG 5472 Leu Asp Val Glu Glu Pro Asp Ser Ala Asn Ser Ser Phe Tyr Ser Thr 1810 1815 1820 CGG TCT GCT CCT GCT TCC CAG GCT AGC CTG CGA GCC ACC TCC TCT ACT 5520 Arg Ser Ala Pro Ala Ser Gin Ala Ser Leu Arg Ala Thr Ser Ser Thr 1825 1830 1835 1840 CAG TCT CTA GCT CGC CTG GGT TCT CCC GAT TAT GGC AAC TCA GCC CTG 5568 Gin Ser Leu Ala Arg Leu Gly Ser Pro Asp Tyr Gly Asn Ser Ala Leu 1845 1850 1855 CTC AGC TTG CCT GGC TAC CGC CCC ACC ACT CGC AGT TCT GCT CGT CGT 5616 Leu Ser Leu Pro Gly Tyr Arg Pro Thr Thr Arg Ser Ser Ala Arg Arg 1860 1865 1870 TCC CAG GCC GGG GTG TCC AGT GGG GCC CCT CCA GGA AGG AAC AGC TTC 5664 Ser Gin Ala Gly Val Ser Ser Gly Ala Pro Pro Gly Arg Asn Ser Phe 1875 1880 1885 TAC ATG GGC ACT TGC CAG GAT GAG CCT GAG CAG CTG GAT GAC TGG AAC 5712 Tyr Met Gly Thr Cys Gin Asp Glu Pro Glu Gin Leu Asp Asp Trp Asn 1890 1895 1900 CGC ATT GCA GAG CTG CAG CAG CGC AAT CGA GTG TGC CCC CCA CAT CTG 5760 Arg He Ala Glu Leu Gin Gin Arg Asn Arg Val Cys Pro Pro His Leu 1905 1910 1915 1920 AAG ACC TGC TAT CCC CTG GAG TCC AGG CCT TCC CTG AGC CTG GGC ACC 5808 Lys Thr Cys Tyr Pro Leu Glu Ser Arg Pro Ser Leu Ser Leu Gly Thr 1925 1930 1935 ATC ACA GAT GAG GAG ATG AAA ACT GGA GAC CCC CAA GAG ACC CTG CGC 5856 He Thr Asp Glu Glu Met Lys Thr Gly Asp Pro Gin Glu Thr Leu Arg 1940 1945 1950 CGA GCC AGC ATG CAG CCA ATC CAG ATA GCC GAG GGC ACT GGC ATC ACC 5904 Arg Ala Ser Met Gin Pro He Gin He Ala Glu Gly Thr Gly He Thr 1955 1960 1965 ACC CGG CAG CAG CGC AAA CGG GTC TCC CTA GAG CCC CAC CAG GGC CCT 5952 Thr Arg Gin Gin Arg Lys Arg Val Ser Leu Glu Pro His Gin Gly Pro 1970 1975 1980 GGA ACT CCT GAG TCT AAG AAG GCC ACC AGC TGT TTC CCA CGC CCC ATG 6000 Gly Thr Pro Glu Ser Lys Lys Ala Thr Ser Cys Phe Pro Arg Pro Met 1985 1990 1995 2000 ACT CCC CGA GAC CGA CAT GAA GGG CGC AAA CAG AGC ACT ACT GAG GCC 6048 Thr Pro Arg Asp Arg His Glu Gly Arg Lys Gin Ser Thr Thr Glu Ala 2005 2010 2015 CAG AAG AAA GCA GCT CCA GCT TCT ACT AAA CAG GCT GAC CGG CGC CAG 6096 Gin Lys Lys Ala Ala Pro Ala Ser Thr Lys Gin Ala Asp Arg Arg Gin 2020 2025 2030 TCG ATG GCC TTC AGC ATC CTC AAC ACA CCC AAG AAG CTA GGG AAC AGC 6144 Ser Met Ala Phe Ser He Leu Asn Thr Pro Lys Lys Leu Gly Asn Ser 2035 2040 2045 CTT CTG CGG CGG GGA GCC TCA AAG AAG GCC CTG TCC AAG GCT TCC CCC 6192 Leu Leu Arg Arg Gly Ala Ser Lys Lys Ala Leu Ser Lys Ala Ser Pro 2050 2055 2060 AAC ACT CGC AGT GGA ACC CGC CGT TCT CCG CGC ATT GCC ACC ACC ACA 6240 Asn Thr Arg Ser Gly Thr Arg Arg Ser Pro Arg He Ala Thr Thr Thr 2065 2070 2075 2080 GCC AGT GCC GCC ACT GCT GCC GCC ATT GGT GCC ACC CCT CGA GCC AAG 6288 Ala Ser Ala Ala Thr Ala Ala Ala He Gly Ala Thr Pro Arg Ala Lys 2085 2090 2095 GGC AAG GCA AAG CAC TAA 6306 Gly Lys Ala Lys His 2100 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2101 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Thr Leu His Ala Thr Arg Gly Ala Ala Leu Leu Ser Trp Val Asn 1 5 10 15 Ser Leu His Val Ala Asp Pro Val Glu Ala Val Leu Gin Leu Gin Asp 20 25 30 Cys Ser He Phe He Lys He He Asp Arg He His Gly Thr Glu Glu 35 40 45 Gly Gin Gin He Leu Lys Gin Pro Val Ser Glu Arg Leu Asp Phe Val 50 55 60 Cys Ser Phe Leu Gin Lys Asn Arg Lys His Pro Ser Ser Pro Glu Cys 65 70 75 80 Leu Val Ser Ala Gin Lys Val Leu Glu Gly Ser Glu Leu Glu Leu Ala 85 90 95 Lys Met Thr Met Leu Leu Leu Tyr His Ser Thr Met Ser Ser Lys Ser 100 105 110 Pro Arg Asp Trp Glu Gin Phe Glu Tyr Lys He Gin Ala Glu Leu Ala 115 120 125 Val He Leu Lys Phe Val Leu Asp His Glu Asp Gly Leu Asn Leu Asn 130 135 140 Glu Asp Leu Glu Asn Phe Leu Gin Lys Ala Pro Val Pro Ser Thr Cys 145 150 155 160 Ser Ser Thr Phe Pro Glu Glu Leu Ser Pro Pro Ser His Gin Ala Lys 165 170 175 Arg Glu He Arg Phe Leu Glu Leu Gin Lys Val Ala Ser Ser Ser Ser 180 185 190 Gly Asn Asn Phe Leu Ser Gly Ser Pro Ala Ser Pro Met Gly Asp He 195 200 205 Leu Gin Thr Pro Gin Phe Gin Met Arg Arg Leu Lys Lys Gin Leu Ala 210 215 220 Asp Glu Arg Ser Asn Arg Asp Glu Leu Glu Leu Glu Leu Ala Glu Asn 225 230 235 240 Arg Lys Leu Leu Thr Glu Lys Asp Ala Gin He Ala Met Met Gin Gin 245 250 255 Arg He Asp Arg Leu Ala Leu Leu Asn Glu Lys Gin Ala Ala Ser Pro 260 265 270 Leu Glu Pro Lys Glu Leu Glu Glu Leu Arg Asp Lys Asn Glu Ser Leu 275 280 285 Thr Met Arg Leu His Glu Thr Leu Lys Gin Cys Gin Asp Leu Lys Thr 290 295 300 Glu Lys Ser Gin Met Asp Arg Lys He Asn Gin Leu Ser Glu Glu Asn 305 310 315 320 Gly Asp Leu Ser Phe Lys Leu Arg Glu Phe Ala Ser His Leu Gin Gin 325 330 335 Leu Gin Asp Ala Leu Asn Glu Leu Thr Glu Glu His Ser Lys Ala Thr 340 345 350 Gin Glu Trp Leu Glu Lys Gin Ala Gin Leu Glu Lys Glu Leu Ser Ala 355 360 365 Ala Leu Gin Asp Lys Lys Cys Leu Glu Glu Lys Asn Glu He Leu Gin 370 375 380 Gly Lys Leu Ser Gin Leu Glu Glu His Leu Ser Gin Leu Gin Asp Asn 385 390 395 400 Pro Pro Gin Glu Lys Gly Glu Val Leu Gly Asp Val Leu Gin Leu Glu 405 410 415 Thr Leu Lys Gin Glu Ala Ala Thr Leu Ala Ala Asn Asn Thr Gin Leu 420 425 430 Gin Ala Arg Val Glu Met Leu Glu Thr Glu Arg Gly Gin Gin Glu Ala 435 440 445 Lys Leu Leu Ala Glu Arg Gly His Phe Glu Glu Glu Lys Gin Gin Leu 450 455 460 Ser Ser Leu He Thr Asp Leu Gin Ser Ser He Ser Asn Leu Ser Gin 465 470 475 480 Ala Lys Glu Glu Leu Glu Gin Ala Ser Gin Ala His Gly Ala Arg Leu 485 490 495 Thr Ala Gin Val Ala Ser Leu Thr Ser Glu Leu Thr Thr Leu Asn Ala 500 505 510 Thr He Gin Gin Gin Asp Gin Glu Leu Ala Gly Leu Lys Gin Gin Ala 515 520 525 Lys Glu Lys Gin Ala Gin Leu Ala Gin Thr Leu Gin Gin Gin Glu Gin 530 535 540 Ala Ser Gin Gly Leu Arg His Gin Val Glu Gin Leu Ser Ser Ser Leu 545 550 555 560 Lys Gin Lys Glu Gin Gin Leu Lys Glu Val Ala Glu Lys Gin Glu Ala 565 570 575 Thr Arg Gin Asp His Ala Gin Gin Leu Ala Thr Ala Ala Glu Glu Arg 580 585 590 Glu Ala Ser Leu Arg Glu Arg Asp Ala Ala Leu Lys Gin Leu Glu Ala 595 600 605 Leu Glu Lys Glu Lys Ala Ala Lys Leu Glu He Leu Gin Gin Gin Leu 610 615 620 Gin Val Ala Asn Glu Ala Arg Asp Ser Ala Gin Thr Ser Val Thr Gin 625 630 635 640 Ala Gin Arg Glu Lys Ala Glu Leu Ser Arg Lys Val Glu Glu Leu Gin 645 650 655 Ala Cys Val Glu Thr Ala Arg Gin Glu Gin His Glu Ala Gin Ala Gin 660 665 670 Val Ala Glu Leu Glu Leu Gin Leu Arg Ser Glu Gin Gin Lys Ala Thr 675 680 685 Glu Lys Glu Arg Val Ala Gin Glu Lys Asp Gin Leu Gin Glu Gin Leu 690 695 700 Gin Ala Leu Lys Glu Ser Leu Lys Val Thr Lys Gly Ser Leu Glu Glu 705 710 715 720 Glu Lys Arg Arg Ala Ala Asp Ala Leu Glu Glu Gin Gin Arg Cys He 725 730 735 Ser Glu Leu Lys Ala Glu Thr Arg Ser Leu Val Glu Gin His Lys Arg 740 745 750 Glu Arg Lys Glu Leu Glu Glu Glu Arg Ala Gly Arg Lys Gly Leu Glu . 755 760 765 Ala Arg Leu Leu Gin Leu Gly Glu Ala His Gin Ala Glu Thr Glu Val 770 775 780 Leu Arg Arg Glu Leu Ala Glu Ala Met Ala Ala Gin His Thr Ala Glu 785 790 795 800 Ser Glu Cys Glu Gin Leu Val Lys Glu Val Ala Ala Trp Arg Asp Gly 805 810 815 Tyr Glu Asp Ser Gin Gin Glu Glu Ala Gin Tyr Gly Ala Met Phe Gin 820 825 830 Glu Gin Leu Met Thr Leu Lys Glu Glu Cys Glu Lys Ala Arg Gin Glu 835 840 845 Leu Gin Glu Ala Lys Glu Lys Val Ala Gly He Glu Ser His Ser Glu 850 855 860 Leu Gin He Ser Arg Gin Gin Asn Lys Leu Ala Glu Leu His Ala Asn 865 870 875 880 Leu Ala Arg Ala Leu Gin Gin Val Gin Glu Lys Glu Val Arg Ala Gin 885 890 895 Lys Leu Ala Asp Asp Leu Ser Thr Leu Gin Glu Lys Met Ala Ala Thr 900 905 910 Ser Lys Glu Val Ala Arg Leu Glu Thr Leu Val Arg Lys Ala Gly Glu 915 920 925 Gin Gin Glu Thr Ala Ser Arg Glu Leu Val Lys Glu Pro Ala Arg Ala 930 935 940 Gly Asp Arg Gin Pro Glu Trp Leu Glu Glu Gin Gin Gly Arg Gin Phe 945 950 955 960 Cys Ser Thr Gin Ala Ala Leu Gin Ala Met Glu Arg Glu Ala Glu Gin 965 970 975 Met Gly Asn Glu Leu Glu Arg Leu Arg Ala Ala Leu Met Glu Ser Gin 980 985 990 Gly Gin Gin Gin Glu Glu Arg Gly Gin Gin Glu Arg Glu Val Ala Arg 995 1000 1005 Leu Thr Gin Glu Arg Gly Arg Ala Gin Ala Asp Leu Ala Leu Glu Lys 1010 1015 1020 Ala Ala Arg Ala Glu Leu Glu Met Arg Leu Gin Asn Ala Leu Asn Glu 1025 1030 1035 1040 Gin Arg Val Glu Phe Ala Thr Leu Gin Glu Ala Leu Ala His Ala Leu 1045 1050 1055 Thr Glu Lys Glu Gly Lys Asp Gin Glu Leu Ala Lys Leu Arg Gly Leu 1060 1065 1070 Glu Ala Ala Gin He Lys Glu Leu Glu Glu Leu Arg Gin Thr Val Lys 1075 1080 1085 Gin Leu Lys Glu Gin Leu Ala Lys Lys Glu Lys Glu His Ala Ser Gly 1090 1095 1100 Ser Gly Ala Gin Ser Glu Ala Ala Gly Arg Thr Glu Pro Thr Gly Pro 1105 1110 1115 1120 Lys Leu Glu Ala Leu Arg Ala Glu Val Ser Lvs Leu Glu Gin Gin Cys 1125 1130 * 1135 Gin Lys Gin Gin Glu Gin Ala Asp Ser Leu Glu Arg Ser Leu Glu Ala 1140 1145 1150 Glu Arg Ala Ser Arg Ala Glu Arg Asp Ser Ala Leu Glu Thr Leu Gin 1155 1160 1165 Gly Gin Leu Glu Glu Lys Ala Gin Glu Leu Gly His Ser Gin Ser Ala 1170 1175 1180 Leu Ala Ser Ala Gin Arg Glu Leu Ala Ala Phe Arg Thr Lys Val Gin 1185 1190 1195 1200 Asp His Ser Lys Ala Glu Asp Glu Trp Lys Ala Gin Val Ala Arg Gly 1205 1210 1215 Arg Gin Glu Ala Glu Arg Lys Asn Ser Leu He Ser Ser Leu Glu Glu 1220 1225 1230 Glu Val Ser He Leu Asn Arg Gin Val Leu Glu Lys Glu Gly Glu Ser 1235 1240 1245 Lys Glu Leu Lys Arg Leu Val Met Ala Glu Ser Glu Lys Ser Gin Lys 1250 1255 1260 Leu Glu Glu Ser Cys Ala Cys Cys Arg Gin Arg Gin Pro Ala Thr Val 1265 1270 1275 1280 Pro Glu Leu Gin Asn Ala Ala Leu Leu Cys Gly Arg Arg Cys Arg Ala 1285 1290 1295 Ser Gly Arg Glu Ala Glu Lys Gin Arg Val Ala Ser Glu Asn Leu Arg 1300 1305 1310 Gin Glu Leu Thr Ser Gin Ala Glu Arg Ala Glu Glu Leu Gly Gin Glu 1315 1320 1325 Leu Lys Ala Trp Gin Glu Lys Phe Phe Gin Lys Glu Gin Ala Leu Ser 1330 1335 1340 Thr Leu Gin Leu Glu His Thr Ser Thr Gin Ala Leu Val Ser Glu Leu 1345 1350 1355 1360 Leu Pro Ala Lys His Leu Cys Gin Gin Leu Gin Ala Glu Gin Ala Ala 1365 1370 1375 Ala Glu Lys Arg His Arg Glu Glu Leu Glu Gin Ser Lys Gin Ala Ala 1380 1385 1390 Gly Gly Leu Arg Ala Glu Leu Leu Arg Ala Gin Arg Glu Leu Gly Glu 1395 1400 1405 Leu He Pro Leu Arg Gin Lys Val Ala Glu Gin Glu Arg Thr Ala Gin 1410 1415 1420 Gin Leu Arg Ala Glu Lys Ala Ser Tyr Ala Glu Gin Leu Ser Met Leu 1425 1430 1435 1440 Lys Lys Ala His Gly Leu Leu Ala Glu Glu Asn Arg Gly Leu Gly Glu 1445 1450 1455 Arg Ala Asn Leu Gly Arg Gin Phe Leu Glu Val Glu Leu Asp Gin Ala 1460 1465 1470 Arg Glu Lys Tyr Val Gin Glu Leu Ala Ala Val Arg Ala Asp Ala Glu 1475 1480 1485 Thr Arg Leu Ala Glu Val Gin Arg Glu Ala Gin Ser Thr Ala Arg Glu 1490 1495 1500 Leu Glu Val Met Thr Ala Lys Tyr Glu Gly Ala Lys Val Lys Val Leu 1505 1510 1515 1520 Glu Glu Arg Gin Arg Phe Gin Glu Glu Arg Gin Lys Leu Thr Ala Gin 1525 1530 1535 Val Glu Glu Leu Ser Lys Lys Leu Ala Asp Ser Asp Gin Ala Ser Lys 1540 1545 1550 Val Gin Gin Gin Lys Leu Lys Ala Val Gin Ala Gin Gly Gly Glu Ser 1555 1560 1565 Gin Gin Glu Ala Gin Arg Phe Gin Ala Gin Leu Asn Glu Leu Gin Ala 1570 1575 1580 Gin Leu Ser Gin Lys Glu Gin Ala Ala Glu His Tyr Lys Leu Gin Met 1585 1590 1595 1600 Glu Lys Ala Lys Thr His Tyr Asp Ala Lys Lys Gin Gin Asn Gin Glu 1605 1610 1615 Leu Gin Glu Gin Leu Arg Ser Leu Glu Gin Leu Gin Lys Glu Asn Lys 1620 1625 1630 Glu Leu Arg Ala Glu Ala Glu Arg Leu Gly His Glu Leu Gin Gin Ala 1635 1640 1645 Gly Leu Lys Thr Lys Glu Ala Glu Gin Thr Cys Arg His Leu Thr Ala 1650 1655 1660 Gin Val Arg Ser Leu Glu Ala Gin Val Ala His Ala Asp Gin Gin Leu 1665 1670 1675 1680 Arg Asp Leu Gly Lys Phe Gin Val Ala Thr Asp Ala Leu Lys Ser Arg 1685 1690 1695 Glu Pro Gin Ala Lys Pro Gin Leu Asp Leu Ser He Asp Ser Leu Asp 1700 1705 1710 Leu Ser Cys Glu Glu Gly Thr Pro Leu Ser He Thr Ser Lys Leu Pro 1715 1720 1725 Arg Thr Gin Pro Asp Gly Thr Ser Val Pro Gly Glu Pro Ala Ser Pro 1730 1735 1740 He Ser Gin Arg Leu Pro Pro Lys Val Glu Ser Leu Glu Ser Leu Tyr 1745 1750 , 1755 1760 Phe Thr Pro He Pro Ala Arg Ser Gin Ala Pro Leu Glu Ser Ser Leu 1765 1770 1775 Asp Ser Leu Gly Asp Val Phe Leu Asp Ser Gly Arg Lys Thr Arg Ser 1780 1785 1790 Ala Arg Arg Arg Thr Thr Gin He He Asn He Thr Met Thr Lys Lys 1795 1800 1805 Leu Asp Val Glu Glu Pro Asp Ser Ala Asn Ser Ser Phe Tyr Ser Thr 1810 1815 1820 Arg Ser Ala Pro Ala Ser Gin Ala Ser Leu Arg Ala Thr Ser Ser Thr 1825 1830 1835 1840 Gin Ser Leu Ala Arg Leu Gly Ser Pro Asp Tyr Gly Asn Ser Ala Leu 1845 1850 1855 Leu Ser Leu Pro Gly Tyr Arg Pro Thr Thr Arg Ser Ser Ala Arg Arg 1860 1865 1870 Ser Gin Ala Gly Val Ser Ser Gly Ala Pro Pro Gly Arg Asn Ser Phe 1875 1880 1885 Tyr Met Gly Thr Cys Gin Asp Glu Pro Glu Gin Leu Asp Asp Trp Asn 1890 1895 1900 Arg He Ala Glu Leu Gin Gin Arg Asn Arg Val Cys Pro Pro His Leu 1905 1910 1915 1920 Lys Thr Cys Tyr Pro Leu Glu Ser Arg Pro Ser Leu Ser Leu Gly Thr 1925 1930 1935 He Thr Asp Glu Glu Met Lys Thr Gly Asp Pro Gin Glu Thr Leu Arg 1940 1945 1950 Arg Ala Ser Met Gin Pro He Gin He Ala Glu Gly Thr Gly He Thr 1955 1960 1965 Thr Arg Gin Gin Arg Lys Arg Val Ser Leu Glu Pro His Gin Gly Pro 1970 1975 1980 Gly Thr Pro Glu Ser Lys Lys Ala Thr Ser Cys Phe Pro Arg Pro Met 1985 1990 1995 2000 Thr Pro Arg Asp Arg His Glu Gly Arg Lys Gin Ser Thr Thr Glu Ala 2005 2010 2015 Gin Lys Lys Ala Ala Pro Ala Ser Thr Lys Gin Ala Asp Arg Arg Gin 2020 2025 2030 Ser Met Ala Phe Ser He Leu Asn Thr Pro Lys Lys Leu Gly Asn Ser 2035 2040 2045 Leu Leu Arg Arg Gly Ala Ser Lys Lys Ala Leu Ser Lys Ala Ser Pro 2050 2055 2060 Asn Thr Arg Ser Gly Thr Arg Arg Ser Pro Arg He Ala Thr Thr Thr 2065 2070 2075 2080 Ala Ser Ala Ala Thr Ala Ala Ala He Gly Ala Thr Pro Arg Ala Lys 2085 2090 2095 Gly Lys Ala Lys His 2100 (2) INFORMATION FOR SEQ ID NO:5: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 353 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: DNA (ix)FEATURE: (A) NAME/KEY: mRNA (B) LOCATION: 1..353 (D) OTHER INFORMATION: /note= "ANTI-SENSE SEQUENCE TO PART OF THE MTl MRNA TRANSCRIPT: N TERMINUS OF PROTEN CODING SEQUENCE AND UPSTREAM 53 NUCLEOTIDES." (ix)FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (298..300) (D) OTHER INFORMATION: /note= "MTl INITIATION CODON SEQUENCE ON COMPLEMENTARY STRAND." (xi)SEQUENCE DESCRIPTION: SEQ ID NO:5: CTCAATTTTA ACTTGTTCTT GTTTTTCTCG TTGTGCAAGG CGAGCTGCAA CTTCTTCAGG 60 TGGTCGCTCC CTTATAGAAG ATGAGGATGC TTCTGAAAGT GCAGGTGTGG GTTTTCCTTC 120 ACCAATTTCA GGGTGATCAG TTTTTAAAGA TTCCTCAGGC TGAACTGCAG GGGCTGGGAC 180 CGACAGGGTA TCACCTGCTG CAGAAATAAT TTGAGCCGCT TCTGTAGGTG CTGTTGCTGA 240 AGCTGGAGTA TCTCCCTTTT GTTGTTGGAG TTGTGAGGCA GGCTGTTTAG ATTCTTTCAT 300 TACTTCTGAT ACACTAGAGA TTTTTAGTGG ACCCGACTGA ATCGATTTCT TTG 353 (2) INFORMATION FOR SEQ ID NO:6: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 348 base pairs (B) TYPE: nucleic acid (C) STRWDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: DNA (ix) FEATURE: (A) NAME/KEY: mRNA (B) LOCATION: 1..348 (D) OTHER INFORMATION: /note= ".ANTISENSE SEQUENCE TO P.ART OF MT2 TRANSCRIPT: N TERMINUS OF PROTEIN CODING REGION .AND UPSTREAM 48 NUCLEOTIDES." (ix)FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (298..300) (D) OTHER INFORMATION: /note= "MT2 INITIATION CODON SEQUENCE ON COMPLEMENTARY STRAND." (xi)SEQUENCE DESCRIPTION: SEQ ID NO:6: CATGGTCATC TTCGCCAGTT CCAGCTCTGA TCCCTCTAGC ACCTTCTGTG CAGATACCAG 60 GCGTTCTGGG GAAGAGGGAT GTTTTCGATT TTTCTGCAGA AAACTGCACA CAAAGTCCAG 120 TCTCTCTGAC ACCGGCTGCT TCTTGATTTG CTGTCCCTCT TCAGTGCCAT GGATTCTGTC 180 AATGATCTTG ATGAAGATGC TGCAGTCCTG GAGCTGCAGC ACAGCCTCCA CAGGGTCAGC 240 CACGTGTAGA CTGTTCACCC AAGAGAGGAG TGCAGCCCCC CGGGTGGCGT GGAGTGTCAT 300 CTTGGTGATG CCAGACAGTC ACTCCAATGC GCCTGTAATC CCAGCTAC 348

Claims: What is claimed is: 1. An isolated nucleic acid comprising the DNA sequence of Seq. ID No. 1, including variants thereof. 2. An isolated nucleic acid that hybridizes with the DNA sequence of Seq. ID No. 1 under stringent hybridization conditions. 3. A host cell transfected with the nucleic acid of claim 1 or 2. 4. A vector comprising the nucleic acid of claim 1 or 2. 5. A protein or protein fragment encoded by the DNA sequence of Seq. ID No. 1, including variants thereof, in combination with an adjuvant. 6. A protein, produced by recombinant DNA in a host cell and isolated from said host cell, said recombinant DNA having the sequence of Seq. ID No. 1, including variants thereof. 7. A binding protein that binds to an epitope on the protein of claim 6. 8. The binding protein of claim 7 wherein said binding protein is an antibody or an antibody fragment. 9. A method of manufacturing an antibody for use in the detection of abnormal cell types, the method comprising the steps of: a) combining a recombinantly-produced protein or protein fragment encoded by the DNA of Seq. ID No. l or 3/, including a variant thereof, with v ' an adjuvant to form a composition suitable for injection into a mammal; b) injecting the composition into a mammal to induce antibody production in said mammal against said recombinantly- produced protein or protein fragment; and c) isolating said antibody from said mammal. 10. The method of claim 9 wherein said step of isolating said antibody from said mammal is performed by isolating from said mammal a cell producing said antibody. 11. A method of detecting an abnormal cell type in a sample containing cells or cell nucleus debris, the method comprising the steps of: (a) contacting the sample with a binding protein that recognizes an epitope on a marker protein comprising an amino acid sequence encoded by the DNA of Seq. ID No. 1 or 3 or a variant thereof; and (b) detecting the presence in the sample of said marker protein or a fragment thereof. 12. The method of claim 9 or 11 wherein said abnormal cell type is a malignant cell type. 13. The method of claim 12 wherein said malignant cell type is characteristic of a malignant bladder, breast, prostate, lung, colon, ovary or cervix cell type. 14. The method of claim 11 wherein said binding protein is an antibody that binds specifically to an epitope on said marker protein or protein fragment. 15. The method of claim 14 wherein said antibody has a binding affinity for said epitope greater than IOV 1 . 16. The method of claim 15 wherein said antibody has a binding affinity greater than 10 7 M -1 . 17. The method of claim 11 comprising the additional step of quantitating the abundance of said marker protein in said sample. 18. The method of claim 11 wherein said sample comprises a body fluid. 19. The method of claim 18 wherein said body fluid is selected from the group consisting of serum, plasma, blood, urine, semen, vaginal secretions, spinal fluid, ascitic fluid, peritoneal fluid, sputum, and breast exudate. 20. A method for determining the degree of cell death in a tissue, the method comprising the steps of: (a) contacting a sample with a binding protein that recognizes an epitope on a marker protein for cell death, said marker protein comprising an amino acid sequence encoded by the DNA of Seq. ID No. 1 or 3 or a variant thereof; and (b) detecting the concentration of said marker protein or protein fragment released from the cells of said tissue, said marker protein or protein fragment comprising an amino acid sequence encoded by the DNA sequence of Seq. ID No. 1 or 3 or a variant thereof, the concentration of said marker protein or protein fragment detected being indicative of the degree of cell death in said tissue. 21. The method of claim 20 comprising the additional steps of: c) repeating, at intervals, the steps of detecting the concentration of said marker protein or protein fragments thereof; and d) comparing said detected concentrations, wherein changes in said detected concentrations are indicative of the status of said tissue. 22. The method of claim 20 for use in monitoring change in the status of a disease or the efficacy of a therapy, wherein a decrease in said detected concentrations is indicative of a decrease in cell death, and an increase in said detected concentrations is indicative of an increase in cell death. 23. the method of claim 20 wherein said tissue is characteristic of breast, prostate, lung, colon, ovary, bladder or cervical tissue. 24. A method of detecting an abnormal cell type in a sample containing cells or cell nucleus debris, the method comprising the steps of: a) contacting the sample with a nucleic acid that hybridizes specifically to an mRNA transcript encoded by the DNA sequence of Seq. ID No. 1 or Seq. 3, said transcript, when translated, encoding the amino acid sequence of Seq. ID No 1 or Seq. ID No. 3 or a variant thereof; and b) detecting the presence in the sample of said mRNA transcript or a fragment or variant thereof. 25. The method of claim 24 wherein said abnormal cell type is a malignant cell type. 26. The method of claim 25 wherein said malignant cell type is characteristic of a malignant breast, prostate, lung, colon, cervix or bladder cell type. 27. The method of claim 24 wherein said nucleic acid hybridizes with said mRNA transcript under stringent hybridization conditions. 28. The method of claim 24 comprising the additional step of quantitating the abundance of said transcript in said sample. 29. Use of a molecule capable of binding to the mRNA transcript or protein product of HT1 or MT2, including variants thereof, for the manufacture of a cancer therapeutic agent. 30. Use according to claim 29 wherein said canor therapeutic agent is for the treatment of breast, prostate, cervix, ovarian, bladder, colon, prostate or lung cancer. 31. Use according to claim 30 wherein said molecule is an oligonucleotide complementary to at least a portion of the DNA sequence of Seq. ID No. 1 or 3. 32. Use according to claim 31 wherein said oligonucleotide is a synthetic oligonucleotide and comprises at least a portion of the sequence of Seq. ID No. 5 or 6. 33. Use according to claim 29 wherein said molecule is a member of a binding pair capable of binding HT1 or HT2 or a variant thereof substantially irreversibly. 34. Use according to claim 33 wherein said member of said binding pair binds MTl or MT2 or a variant thereof with an affinity greater than about 10 9 M "1 . 35. A synthetic oligonucleotide in admixture with a pharmaceutical carrier for use in the manufacture of a therapeutic agent, said synthetic oligonucleotide comprising a sequence complementary to at least a portion of the mRNA transcript of MTl or MT2 or a variant thereof. 36. The synthetic oligonucleotide of claim 35 comprising a sequence complementary to at least a portion of the DNA sequence of Seq. ID No. 1 or 3 or a variant thereof. 37. The synthetic oligonucleotide of claim 35 comprising at least a portion of the sequence of Seq. ID No. 5 or 6 or a variant thereof. 38. The synthetic oligonucletide of claim 35 being at least 15 nucleotides in length. 39. A binding protein for use in the manufacture of a medicament, said binding protein having a binding affinity of greater than about 10 M~ for the protein encoded by the DNA of Seq. ID No. 1 or 3, or a variant thereof.

Inventors: LIDGARD GRAHAM P, TOUKATLY GARY, LIDGARD, GRAHAM, P., TOUKATLY, GARY
Applicants: MATRITECH INC, MATRITECH, INC.
Application year: 1993
Main classification: C12N15
IPC codes: A61K31, A61K38, A61K39, A61K48, A61P35, C07H21, C07K14, C07K16, C12N15, C12P21, C12Q1, C12R1, G01N33